58th ANNUAL MEETING SOCIETY OF THROMBOSIS AND HAEMOSTASIS RESEARCH

Translational medicine on the road to tailored therapies February 12 –15, 2014 Vienna, Austria Prefinal Programme www.gth2014.orgU1

Contents

Contents...... 1

Floor Plans – Lecture Hall Overview...... 2

Sponsors ...... 4

Welcome Address ...... 5

Congress Organization ...... 6

Registration Area...... 8

General Congress Information ...... 10

Media (Preview) Center ...... 12

Guidelines for Speakers ...... 12

Guidelines for Chairpersons ...... 13

Guidelines for Poster Presenters...... 13

Awards ...... 14

Best Abstract Prizes ...... 14

Programme at a Glance...... 15

Scientific Programme – Wednesday, February 12, 2014 ...... 19

Scientific Programme – Thursday, February 13, 2014 ...... 27

Scientific Programme – Friday, February 14, 2014...... 37

Scientific Programme – Saturday, February 15, 2014 ...... 49

Poster Sessions – Thursday, February 13, 2014 ...... 54

Poster Sessions – Friday, February 14, 2014 ...... 69

Exhibition ...... 83

General Information Vienna ...... 84

Travel to Vienna ...... 85

City Map Vienna...... 86

Underground Map Vienna ...... 87

1 Floor Plans – Lecture Hall Overview

GROUND FLOOR

SCHWEIZERHOF

SCHWEIZERTOR

BOTSCHAFERTSTIEGE

(FRANZENSPLATZ)

FOYER- SCHATZ- SCHATZKAMMERSAAL SCHLOSSERGANG KAMMER- SAAL

LICHTHOF

WC WC WC

FORUM WC

AUM

RO

STALTER-

BÜ

LIFT VORR GANG LIFT

VERAN

ARZTZIMMER MEDIA CENTER

DUNGS FESTSTIEGE GARDEHALLE I

VERBIN

BURGPASSAGE

BIBLIOTHEKSHOF GARDEHALLE II

GARTENSAAL

LE STER HOFBURG PRINZ EUGEN SAAL

ENHAL FOYER

W) CENTER SEIT ERZHERZOG KARL SAAL

+

+ LIFT HELDENPLATZ UITE

ENTRANCE HELDENPLATZ

LEGEND

= LECTURES = REGISTRATION

= EXHIBITION = CLOAKROOM

= SCIENTIFIC POSTER = HOSPITALITY SUITE

= MEDIA (PREVIEW) CENTER = CASH BAR

2 Floor Plans – Lecture Hall Overview

MEZZANINE (1st FLOOR)

NINE

KLEINER REDOUTENSAAL

NG RADETZKY-

OUTENSÄLE

BERGA

Ü

RED

MARIA THERESIEN

RADETZKY- THEATERGANG (FRANZENSPLATZ)

MARIA MARIA THERESIEN THERESIEN SCHWEIZERHOF RADETZKY- APP. I

LECTURE KAPELLENGANG HALL KAPELLENHOF

KÜNSTLER- BOTSCHAFTERSTIEGE HOFBURGKAPELLE ZIMMER ENTREE- HOSPITALITY ZIMMER SUITE BAYER HEALTHCARE TRABANTEN- STUBE RITTERSAAL KÜCHE GEHEIME ANTEKAMMER MARMORSAAL E-Verteiler RATSTUBE CASH BAR

WC

WC HOFBURG GALERIE

LIFT LIFT ZEREMONIEN- SAAL SEITENGALERIE

METTERNICHSAAL HELDENPLATZ ORCHESTERGANG

VORSAAL WINTERGARTEN FESTSAAL

CASH BAR

E-Verteiler

er

l

i e

t LIFT

er

V

- E HELDENPLATZ LIFT

3 Sponsors

The organizers of the 58th Annual Meeting of the GTH gratefully acknowledge the support of the following companies

Platinum Sponsors

Gold Sponsors

Silver Sponsors

(as per December 2013)

4 Welcome Address

Dear Colleagues! We are delighted to invite you to the 58th Annual Meeting of the GTH to be held from February 12 to February 15, 2014 in Vienna. In an effort to highlight the translational approach of this meeting we will aim to connect basic research with clinical applications in all areas covered. Therefore we plan to open clinical sessions with a lecture devoted to basic research and vice versa to have a clinical lecture concluding basic research sessions.

A strong focus will also be put on the work of young researchers who will be able to present their results in oral sessions as well as in interactive moderated poster sessions. Based on the fact that GTH decided to go international every second year, we have actively invited other national societies and working groups for GTH 2014 in Vienna and therefore expect also a partially non-German speaking audience. Accordingly, the meeting will be held mainly in English. This applies to the official symposia and abstract presentations and moderations, but is not a pre-requisite for industry-sponsored satellite symposia, which may be held in German (as was also the wish of several sponsors). However we would ask to prepare English slides to give the non-German speaking audience the opportunity to follow the presentations, if given in German.

It should also be emphasized that Vienna, like few other big cities in Europe, offers a wide range of cultural highlights and leisure activities to be enjoyed after a demanding day at the meeting. We hope that we have succeeded in raising your interest in our planned scientific activities and look forward to welcome you in February 2014 at the 58th Annual Meeting of the GTH in Vienna.

Kurt Huber Johann Wojta Congress President Vice President

Vienna, December 2013

5 Congress Organization

Organizer Executive Board Members GTH Gesellschaft für Thrombose- und Christoph BODE, Freiburg (Chair) Hämostaseforschung (GTH) Ulrich WALTER, Mainz (Assistant Chair) Feodor-Lynen-Str. 5 Andreas TIEDE, Hannover (Secretary) 30625 Hannover, Germany Edelgard LINDHOFF-LAST, Frankfurt (Treasurer) Tel.: +49-511-532-8488 Johanna A. KREMER HOVINGA, Berne (Assessor) Fax: +49-511-532-168488 Christoph MALE, Vienna (Assessor) E-Mail: [email protected] Andreas GREINACHER, Greifswald (Assessor) Congress President Congress Secretariat Kurt HUBER, MD, FACC, FESC, FAHA Basic Research Director Stefan KASTL, MD 3rd Department of Medicine, Cardiology Department of Internal Medicine II Wilhelminenhospital Division of Cardiology Montleartstrasse 37 Medical University Vienna 1160 Vienna, Austria Währinger Gürtel 18-20 1090 Vienna, Austria Congress Vice President Johann WOJTA, PhD Clinical Research Department of Internal Medicine II Thomas WEISS, MD, PhD Division of Cardiology 3rd Department of Medicine, Cardiology Medical University Vienna Wilhelminenhospital Währinger Gürtel 18-20 Montleartstrasse 37 1090 Vienna, Austria 1160 Vienna, Austria National Scientific Committee International Scientific Committee Christoph BINDER Marie-Christine ALESSI (FR) Marianne BRODMANN Lina BADIMON (ES) Sabine EICHINGER-HASENAUER Anne-Marie BLOCH MÜNSTER (DK) Margarethe GEIGER Christoph BODE (DE) Christoph KOPP Armando D’ANGELO (IT) Paul A. KYRLE Tilman HACKENG (NL) Irene LANG Sigrun HALVORSEN (NO) Elisabeth MAHLA Robert Gabor KISS (HU) Christoph MALE Wolfgang KORTE (CH) Christine MANNHALTER Gregory LIP (GB) Ingrid PABINGER Nico MARX (DE) Heinz REDL Klaus T. PREISSNER (DE) Jolanta SILLER-MATULA Frits R. ROSENDAAL (NL) Oswald WAGNER Karsten SCHRÖR (DE) Günter WEIGEL Ingebjorg SELJEFLOT (NO) Ansgar WELTERMANN Agneta SIEGBAHN (SE) Michael SPANNAGL (DE) Ulrich WALTER (DE) Christian WEBER (DE)

6 Congress Organization

Congress Office Exhibition/Sponsoring Office

Mondial Congress & Events Medizinische Ausstellungs- und Werbegesellschaft Barbara OBRITZHAUSER, Liesa WESSELY, International Exhibitions & Advertising Denise LEMBÄCKER Sonja CHMELLA, Andrea ETZ, Simone BIACH Operngasse 20B Freyung 6/3 1040 Vienna, Austria 1010 Vienna, Austria Tel.: +43 1 588 04 172, 224, 158 Tel.: +43 1 536 63-32, 42, 37 Fax: +43 1 588 04 185 Fax: +43 1 535 60 16 E-Mail: [email protected] E-Mail: [email protected] www.mondial-congress.com www.media.co.at

Speaker Management CSC Congress and Study Concept GesmbH Franziska BECKMANN Widerhoferplatz 4/3/19 1090 Vienna, Austria Tel.: +43 699 115 16 917 E-Mail: [email protected]

Congress Venue

Hofburg Congress Center Heldenplatz 1010 Vienna, Austria

7 Registration Area

The Registration Area is located on the ground level at the entrance of the congress center. The Mondial Congress & Events team as well as the congress hostesses will be pleased to help you with all inquiries regarding registration, congress materials, hotel accommodation, the networking programme as well as tours and city guidance. Please do not hesitate to approach the team members if there is anything they can do to make your stay more enjoyable.

Opening Hours Registration Counters Wednesday, February 12, 2014 08:00 – 19:30 Thursday, February 13, 2014 08:00 – 19:00 Friday, February 14, 2014 08:00 – 19:00 Saturday, February 15, 2014 08:30 – 12:30

Pre-Registration Counter For participants who are already registered. Please have the confirmation letters sent by Mondial Congress & Events close at hand. If you still have an outstanding payment you may settle your account in cash or by credit card (Visa, MasterCard, American Express, and Diners Club will be accepted). EURO (€) only. Onsite Registration Counter For participants registering and paying their registration fees onsite. You will need to fill out an onsite registration form. Payments will be accepted in cash or by credit card (Visa, MasterCard, American Express and Diners Club will be accepted). EURO (€) only. Tour & Concert Counter For bookings of sightseeing tours, concert and opera tickets. 72 hour public transportation tickets can also be purchased at this counter.

Onsite Registration Fees All prices are given in EUR (€).

Full Congress Registration Onsite Fee Member 280,– Non-Member 330,– Medical Technical Assistant* 110,– Nursing Staff* 110,– PhD Student* 110,– Physician in Training* 110,– Retired member 110,– Student* 90,– * Proof of current status Day Tickets** Onsite Fee needs to be provided, Member 110,– otherwise regular Non-Member 140,– delegate fees Medical Technical Assistant* 60,– (member/non-member) PhD Student* 60,– will apply. Physician in Training* 60,– ** Only one day ticket Retired member 60,– may be purchased.

8 Registration Area

Registration Fee Includes − Admission to all scientific sessions − Admission to scientific poster area − Admission to the commercial exhibition − Congress materials (congress bag, final programme, badge, Abstract CD) − Certificate of Attendance − Admission to the Opening Ceremony & Welcome Reception

Day ticket registration: Entrance to the Opening Ceremony and Welcome Reception is only included for day tickets valid on the day the events take place.

Congress Material Upon registration, you will receive your registration documents including the voucher for your congress bag and your Abstract CD.

Name Badges Participants will receive their name badges when collecting their congress materials. You are kindly requested to wear your name badge during all congress events, including the Opening Ceremony and the Welcome Reception. Please note that admission to scientific sessions is strictly restricted to participants wearing their badges.

The following badge colours are used at the Congress: Delegate nn Day Ticket nn Invited Faculty nn Organizing Committee nn GTH Executive Board nn Staff nn

Payment Please note that all onsite payments should be made in cash or by credit card (Visa, MasterCard, American Express and Diners Club will be accepted). EURO (€) only. Unfortunately, we cannot accept traveller’s cheques, other credit cards, Euro cheques or other currencies.

9 General Congress Information

Congress Language The official language of the congress is English. No simultaneous translation will be provided. Educational Sessions and Workshops may be held in German.

DFP Accreditation The scientific programme of the 58th Annual Meeting of the Society of Thrombosis and Haemostasis Research (ID 491894) is accredited by Austrian Medical Chamber with 30 DFP credit points. DFP credit points can be converted to the German equivalent at your local medical chamber in Germany.

Media (Preview) Center The Media (Preview) Center will be located on the left side of the “Feststiege” – please follow the signs. Staff and equipment will be available for you to arrange and preview your PowerPoint presentation. Please find more detailed information on page 12.

Scientific Poster Area The Scientific Poster Area is located on the ground level throughout the Prinz Eugen Saal and the Erzherzog Karl Saal – please follow the signs. Posters will be on display on Thursday, February 13 and Friday, February 14, 2014. On both days in the afternoon, the presenting authors will be available to explain and discuss their contributions with the interested audience. Please find more detailed information on page 13.

Final Programme & Abstract CD The Final Programme will be published on the Internet at www.gth2014.org. A printed version is included in your congress bag. All abstracts are published in digital form on the Abstract CD which is sponsored by Grifols. Your personal copy can be picked up at the Grifols booth 210 upon presentation of the voucher which is included in your congress bag.

Certificate of Attendance Your Certificate of Attendance will be included in your congress materials available at the registration counter.

Congress Staff The Mondial Congress & Events team members are present at the registration counter and congress hostesses are present in all lecture rooms as well as at the preview centre. Do not hesitate to approach them with queries – they will gladly assist you. You will recognise the Mondial Congress & Events staff wearing black suits with yellow scarves or ties.

10 General Congress Information

Internet Points Internet Points are located on the ground level in the exhibition area. In addition, free WiFi is available throughout the congress venue. Network: HofburgSecured Password: vienna2014

Cloakroom A cloakroom and luggage storage facilities are available on the ground level on the far left. Please follow the signs.

Smoking We have a strict non-smoking policy at the GTH 2014. Smoking inside the congress venue is prohibited. Smoking areas are available outside the main entrance.

First Aid In case of need, please contact the staff at the registration counter.

Car Parking It is highly recommended to use public transportation as there are only a very limited number of parking spots available at the congress center. Within the city center of Vienna, parking charges apply. The following car parks are nearby the congress venue: − Parkgarage Oper (open 24/7) € 39,– per 24 hours Kärntnerstr. 51 − Parkgarage Freyung (open 24/7) € 40,– per 24 hours Herrengasse − Parkgarage Rathaus (open 24/7) € 40,– per 24 hours Universitätsring 1 − Parkgarage Museumsquartier (open 24/7) € 22,– per 24 hours Museumsplatz 1 − Parkgarage Robert Stolz Platz (open 24/7) € 38,– per 24 hours Robert Stolz Platz Price basis 2013

Changes to the Congress Programme In the event of cancellations by speakers or other changes in the main congress programme, no full or partial refund of the registration fee can be made.

Insurance and Liability The organisers cannot be held responsible for any personal injury, loss, damage or accident to private property, or for additional expenses incurred as a result of delays or changes in air, rail, road or other services, strikes, sickness, weather and other causes. All participants are encouraged to make their own arrangements for health and travel insurance.

Further Information Please visit the congress website: www.gth2014.org

11 Media (Preview) Center

The Media (Preview) Center is located on the left side of the “Feststiege” – please follow the signs.

Opening Hours Media (Preview) Center Wednesday, February 12, 2014 08:00 – 19:30 Thursday, February 13, 2014 08:00 – 19:00 Friday, February 14, 2014 08:00 – 19:00 Saturday, February 15, 2014 08:30 – 12:00

Guidelines for Speakers

Presentation slides are to be prepared in English language only. Only PowerPoint presentations are accepted. Speakers should deliver and view/check their PowerPoint presentations at the Media (Preview) Center at least 2 hours prior to the start of the respective session. For sessions starting at 09:00, PowerPoint presentations should be delivered on the previous day.

In order to avoid any delays, speakers are kindly requested to hand in their PowerPoint presentations on CD- ROM or USB. Your PowerPoint presentation will be transferred to the congress server in the Media (Preview) Center and will be available for you on the laptop present in the session at the speaker’s desk in the session room.

For case presentations and videos: Please bring your own laptop. It is crucial however to announce this in the Media Center at least 2 hours prior to your session for organisational reasons!!! Your laptop must be connected to the technical equipment during the break prior to your session by the technician in your session room.

At the Media (Preview) Center, work stations are available to make final changes or additions to presentations. Technical staff is present to assist you if necessary.

All PCs in the lecture rooms are installed with the operating system Windows 7 (or younger) and are equipped with Microsoft Office 2010 (including PowerPoint 2010). The presentations will be projected from a projector to the screen. Double projections are not possible.

Please locate your session room in due time. Please be in your session room at least 15 minutes prior to the start of the session.

12 Guidelines for Chairpersons

Please locate your session room in due time. Please be at your session room at least 15 minutes prior to the start of the session. We may remind you that speakers need to strictly adhere to the time schedule. Panellists should not speak before they are recognised by the chair and must first clearly state their name, institution and country of origin. Chairmen guidelines will be handed to you prior to the session.

Guidelines for Poster Presenters

The Scientific Poster Area is located on the ground level throughout the Prinz Eugen Saal and the Erzherzog Karl Saal – please follow the signs.

Moderated Poster Presentations: 3 minutes of presentation, 3 minutes of discussion each

Poster Mounting Times Posters need to be mounted during the following times for the moderated poster presentations on Thursday, February 13 and Friday, February 14, 2014:

Poster Sessions 1-14: February 13, 2014, 14:30–15:45 Poster authors of Poster Sessions 1-14 are kindly asked to mount their posters between Wednesday (February 12, 2014) 12:00 and Thursday (February 13, 2014) 10:00 at the latest. Posters need to be removed on Thursday (February 13, 2014) between 19:00–19:30.

Poster Sessions 15-28: February 14, 2014, 14:30–15:45 Poster authors of Poster Sessions 15-28 are kindly asked to mount their posters after the removal time of Poster Sessions 1-14, however at the latest on Friday (February 14, 2014) between 08:00–10:00. Posters need to be removed on Friday (February 14, 2014) between 19:00–19:30.

Posters that have not been removed according to the schedule will be disposed of by congress staff.

Poster Dimensions & Mounting Material Posters should be prepared in portrait style, with maximum dimensions of 130 cm length and 90 cm width. Please attach the poster to the board with the corresponding poster placement number. Material for mounting the posters will be available in the Poster Area. If you have any questions regarding your poster(s), please do not hesitate to contact the staff at the registration counter.

13 Awards

The following prizes will be awarded at the 58th Annual Meeting of the Society of Thrombosis and Haemostasis Research (GTH) in Vienna, Austria, during the Opening Ceremony:

Alexander-Schmidt-Award for excellent research studies in the field of haemostaseology Award for young researchers I for excellent research in the field of thrombosis Award for young researchers II for excellent research in the field of bleeding disorders Erwin Deutsch Award of the GTH to promote outstanding scientists in the field of thrombosis and haemostasis research Hans-Egli-Research Grant for young physicians and scientists for a 6-month research project on congenital bleeding disorders Rudolf-Marx-Grant for young scientists from German-speaking countries

Contact GTH Administrative Office Dr. Andreas Tiede E-Mail: [email protected]

Best Abstract Prizes

Certificates will be presented to the twelve best rated basic and clinical abstracts (selected for best abstract presentations). Awardees of the travel support have been contacted by the congress secretariat and are kindly asked to come to the registration counters for formalities.

14 Radezky Appartment I WG5 Ständige Kommission Pädiatrie Schatzkammersaal WG1 Ständige Kommission Hämophilie WG3 MTA Arbeitskreis WG4 AG Erworbene Hämophilie management Gartensaal WG2 AG Perioperatives Gerinnungs SA5 BMS/Pfizer Symposium From Head to Toe Prepared for a DOAC? Geheime Ratstube WS3 Hämophilie- Assistenzpersonal Strukturierte Patientenfortbildung bei Hämophilie SA4 Grifols Symposium Von Willebrand Factor- Disease and Therapy Forum WS2 International FXIII Symposium Recent Advances in Molecular Pathogenesis of FXIII-related Diseases SA2 Roche Diagnostics Deutschland GmbH Symposium Burning Issues in Coagulation Labs SA3 Stago Symposium Pre- and Postanalytic Aspects in Hemostasis Diagnostics. Interactive Examples: Clinician - Diagnostician - Kleiner Redoutensaal WS1 MTA Workshop Hämostase und Autoimmun erkrankungen SA1 LFB Symposium Reliable Approach and New Development in Bleeding Disorders S1 Pearls in Hemostasis and Thrombosis - Case Presentations Festsaal PL1 Plenary Session I Welcome Reception in the Exhibition Areas Opening Ceremony from 19:15 09:00 - 10:30 10:30 - 12:00 12:00 - 12:30 12:30 - 13:30 13:30 - 14:00 14:00 - 15:00 15:00 - 15:30 15:30 - 16:00 16:00 - 17:30 17:30 - 17:45 17:45 - 19:15 Programme at a Glance – Wednesday, February 12, 2014 at a Glance – Wednesday, Programme 15 Poster Area Poster Sessions P1-P14 Schatzkammersaal S6 Free Oral Presentations Bleeding Disorders Gartensaal S5 Joint Meeting with ITALY Autoimmune Disease and Thrombosis SA9 CSL Behring Symposium Hemophilia Treatment in Changing Times SA13 Baxter Symposium Podium Discussion on: „Each Patient is Different – Future Needs for Optimal Treatment” Geheime Ratstube WS4 Symposium of BDDH DOACs - Pro & Contra SA8 Octapharma Symposium Immune Tolerance Induction in Haemophilia A: Between Standard Therapy and Individualized Concepts SA12 Biotest Symposium The Wild Type Factor VIII: Insights and Points of View Forum S4 Best Abstracts CLINICAL RESEARCH SA7 Bayer HealthCare Symposium Update Anticoagulation 2014 SA11 LEO Pharma Symposium Research News in the Management of Venous Thromboembolism Kleiner Redoutensaal S3 Joint Meeting with HUNGARY Poor Inhibitory Response to Antiplatelet Drugs: Platelet Function Measurement and/or Stronger P2Y12- Inhibitors? SA6 Novo Nordisk Pharma GmbH Symposium Turoctocog alfa – a New Recombinant FVIII Resulting from Rational Product Development SA10 Daiichi-Sankyo Symposium Anticoagulation 2014: Where Are We Going? Festsaal PL2 Plenary Session II S2 State-of-the-Art / Joint Meeting with ACCA (ESC) New Issues in Acute Cardiac Care PL3 Plenary Session III 09:00 - 10:00 10:00 - 10:30 10:30 - 12:00 12:00 - 12:30 12:30 - 14:00 14:00 - 14:30 14:30 - 15:45 15:45 - 16:00 16:00 - 17:30 17:30 - 17:45 17:45 - 19:00 Programme at a Glance – Thursday, February 13, 2014 at a Glance – Thursday, Programme 16 Poster Area Poster Sessions P15-P28 Schatzkammersaal S12 Free Oral Presentations Laboratory Issues and Testing Principles S16 Free Oral Presentations Leukocytes and Thrombosis Gartensaal S11 Joint Meeting with THE NETHERLANDS Coagulation & Atherothrombosis SA17 Boehringer Ingelheim Symposium Oral Anticoagulation with Dabigatran SA19 Pfizer Pharma GmbH Symposium Optimising Haemophilia Therapy Geheime Ratstube S10 Hot Topic Platelet Function Testing and Genetic Profiling SA16 Bayer HealthCare Symposium Change in Haemophilia Treatment – an Update S15 LBI Experimental and Clinical Traumatology Coagulopathy in Trauma (TIC) and Infection Forum S9 Best Abstracts BASIC RESEARCH SA15 CSL Behring Symposium All About Coagulation – Factor I to XIII SA18 Alexion Symposium Complement and Coagulation: „Powerful Interaction“ Kleiner Redoutensaal S8 Joint Meeting with DEN- MARK Venous Thromboembolism SA14 Novo Nordisk Pharma GmbH Symposium Haemophilia and Pain – an Interdisciplinary Expert Panel Discussion S14 ÖASA/ASA Is Patient Self- Management of Oral Anticoagulation Still „State-of-the-Art“? Festsaal PL4 Plenary Session IV S7 State-of-the-Art Reperfusion Strategies Networking Evening GTH General Assembly S S13 State-of-the-Art Metabolic Syndrome, Diabetes and Thrombosis PL5 Plenary Session V from 20:00 09:00 - 10:00 10:00 - 10:30 10:30 - 12:00 12:00 - 12:30 12:30 - 14:00 14:00 - 14:15 14:15 - 14:30 14:30 - 15:45 15:45 - 16:15 16:15 - 16:30 16:30 - 18:00 18:00 - 19:00 Programme at a Glance – Friday, February 14, 2014 at a Glance – Friday, Programme 17 Schatzkammersaal S22 Free Oral Presentations ADAMTS13 and von Willebrand Factor Gartensaal S21 Joint Meeting with EPA Platelets, Inflammation and Antiplatelet Drugs Geheime Ratstube S20 Free Oral Presentations Hot Topics - Miscellaneous Forum S19 Joint Meeting with WG Thrombosis (ESC) Aging & Thrombosis Kleiner Redoutensaal S18 Hot Topic Oncology, Coagulation and Thrombosis Festsaal PL6 Plenary Session VI S17 State-of-the-Art Birdging, Bleeding and Transfusion 09:00 - 10:00 10:00 - 10:30 10:30 - 12:00 Programme at a Glance – Saturday, February 15, 2014 at a Glance – Saturday, Programme 18 Scientific Programme – Wednesday, February 12, 2014

09.00 – 12.00 Kleiner Redoutensaal WS1 Workshop/Educational German

MTA Workshop

Hämostase und Autoimmunerkrankungen

Chair: A. Karst (Essen, DE)

WS1-1 Einführung in die Hämostaseologie: Von Morawetz bis Broze Ein Überblick über Mitspieler der Hämostase und deren Funktion A. Karst (Essen, DE)

WS1-2 Autoimmunerkrankungen in der Hämostaseologie TTP und HUS - Pathophysiologie - Diagnostische Möglichkeiten

Heparin induzierte Thrombozytopenie Typ I, Typ II - Pathophysiologie - Diagnostische Möglichkeiten

Andere Autoimmunerkrankungen - Lupus Antikoagulantien - Faktoren-Inhibitoren B. Schuster (Essen, DE)

09.00 – 12.00 Forum WS2 Workshop/Educational

International FXIII Symposium

Recent Advances in Molecular Pathogenesis of FXIII-related Diseases

Chairs: A. Ichinose (Yamagata, JP) H.-P. Kohler (Berne, CH)

WS2-1 Recent Advances in Molecular Pathogenesis of FXIII-related Diseases V. Schroeder, HP. Kohler (Berne, CH)

WS2-2 Alloantibody in a FXIII-A Deficient Patient with Fatal Outcome; Characterization of the Antibody L. Muszbek1, K. Pénzes1, C. Vezina1, Z. Bereczky1, É. Katona1, G.E. Rivard2 (1Debrecen, HU; 2Montreal, CA) Wednesday, February 12, 2014 Wednesday, 19 Scientific Programme – Wednesday, February 12, 2014

09.00 – 12.00 Forum WS2 Workshop/Educational

WS2-3 FXIII Overexpression in Partial Trisomies A. Castiglione, V. Guaran, L. Astolfi, E. Orioli, G. Zeri, D. Gemmati, R. Bovo, A. Montaldi, A. Alghisi, A. Martini (Padua, IT)

WS2-4 Sushi Domains: Not Only a Complement Protein Domain A. Biswas (Bonn, DE)

WS2-5 Molecular Studies on Acquired Hemorrhaphilia Due to Anti-FXIII Autoantibodies (AH13) A. Ichinose, M. Souri, T. Osaki, D. Sugiyama, Y. Magari (Yamagata, JP)

WS2-6 Tocilizumab Induced Acquired FXIII Deficiency in Patients with Rheumatoid Arthritis S. Mokuda, Y. Murata, N. Sawada, K. Matoba, A. Yamada, M. Onishi, Y. Okuda, K. Jouyama, E. Sugiyama, K. Takasugi (Hiroshima, JP)

WS2-7 The Functions of FXIII in Inflammatory Bowel Diseases (tentative title) C. Søndergaard, P.H. Kvist, J.B. Seidelin, O.H. Nielsen (Herlev, DK)

WS2-8 FXIII and Urticaria: a Novel Mechanism in the Pathogenesis? P.R. Criado (Sao Paulo, BR)

WS2-9 Fibrin Matrices, FXIII and Tissue Factor Effects on in Early-term Trophoblast Proliferation and Spreading B. Brenner, A. Snir, B. Paz, G. Ohel, N. Lanir (Haifa, IL)

WS2-10 Multiple Ligands of von Willebrand Factor-binding Protein (vWbp) Promote Staphylococcus aureus Clot Formation in Human Plasma D. Missiakas, L. Thomer, O. Schneewind (Chicago, US)

WS2-11 FXIII-A in Energy Metabolism M. Kaartinen (Montreal, CA)

WS2-12 Oxidative Modification of Fibrinogen and Plasma Fibrin-stabilizing Factor A.V. Bychkova, M.A. Rosenfeld, A.N. Shchegolikhin, V.B. Leonova, M.I. Biryukova, E.A. Kostanova (Moscow, RU)

WS2-13 Methodological Considerations of Working with FXIII and Fibrinogen H. Philippou, R.A. Ariëns (Leeds, UK) Wednesday, February 12, 2014 Wednesday, 20 Scientific Programme – Wednesday, February 12, 2014

09.00 – 12.00 Geheime Ratstube WS3 Workshop/Educational German

Hämophilie-AssistentInnen Workshop

Strukturierte Patientenfortbildung bei Hämophilie

Chair: B. Kulzer (Bad Mergentheim, DE)

10.30 – 12.00 Schatzkammersaal WG1 Working Group German

Ständige Kommission Hämophilie

Chairs: R. Klamroth (Berlin, DE) K. Kurnik (Munich, DE)

WG1-1 Outcome Studien in der Hämophilie K. Berger (Munich, DE)

WG1-2 Patient reported Outcome W. Mondorf (Frankfurt, DE)

WG1-3 Prospektive Studie - der ältere Hämophiliepatient W. Miesbach (Frankfurt, DE)

WG1-4 GTH - Qualitätsprojekt PUPs Aktueller Stand W. Eberl (Braunschweig, DE)

WG1-5 Der interessante Fall, Aktuelles und Verschiedenes

12.30 – 13.30 Festsaal PL1 Plenary Session

Plenary Session I

Chairs: K. Huber (Vienna, AT) J. Wojta (Vienna, AT)

PL1-1 ACE-2. The New World of Functional Genetics J. Penninger (Vienna, AT) Wednesday, February 12, 2014 Wednesday, 21 Scientific Programme – Wednesday, February 12, 2014

14.00 – 15.30 Kleiner Redoutensaal SA1 Satellite Symposium

LFB

Reliable Approach and New Development in Bleeding Disorders

Chairs: I. Pabinger (Vienna, AT) C.-E. Dempfle (Mannheim, DE)

SA1-1 Ageing Patients with von Willebrand Disease: Need for Individualized Treatment W. Miesbach (Frankfurt, DE)

SA1-2 Managing Bleeding Patients with Factor XI Deficiency C. Wermes (Hannover, DE)

SA1-3 A New FVIIa Treatment Option for Haemophilia Patients with Inhibitors S. Chtourou (Les Ulis, FR)

14.00 – 15.30 Forum SA2 Satellite Symposium

Roche Diagnostics Deutschland GmbH

Burning Issues in Coagulation Labs

Chair: E. Lindhoff-Last (Frankfurt, DE)

SA 2–1 New Oral Anti-Coagulants – Confirmation of Study Findings in Routine Use? E. Lindhoff-Last (Frankfurt, DE)

SA 2–2 Perioperative Bleeding Management: Value of PFT? A. Hanke (Hannover, DE)

SA 2–3 Case studies: What Can We Learn from Unusual Ones? D. Peetz (Berlin, DE)

14.00 – 15.30 Gartensaal WG2 Working Group German

AG Perioperatives Gerinnungsmanagement Wednesday, February 12, 2014 Wednesday, 22 Scientific Programme – Wednesday, February 12, 2014

14.00 – 15.00 Schatzkammersaal WG3 Working Group German

MTA Arbeitskreis

Praktische Durchführung der externen Qualitätskontrollen im Hämostaseologischen Labor Problematik und Stolpersteine, was kann aus Sicht der MTA geändert und verbessert werden?

WG3-1 Erfahrungen in der Durchführung externer Qualitätskontrollen des Referenzinstituts Bonn (RFB) H. Stoll (Eschborn, DE)

WG3-2 Erfahrungen in der Durchführung externer Qualitätskontrollen INSTANT/ECAT G. Stöver (Frankfurt, DE)

WG3-3 Erfahrungsaustausch/Diskussion

16.00 – 17.30 Kleiner Redoutensaal S1 Scientific Symposium

Pearls in Hemostasis and Thrombosis - Case Presentations

Chairs: B. Lämmle (Berne, CH/Mainz, DE) H. Schinzel (Mainz, DE) U. Walter (Mainz, DE)

S1-1 Four-year-old Boy with T-cell Leukemia Suffering from Acute Dyspnea O. Beck, H. Schinzel (Mainz, DE)

S1-2 Hematuria in a 61-year-old Woman During Treatment with an Oral Factor Xa-inhibitor S. Eichinger (Vienna, AT)

S1-3 Recurrent Cerebral Ischemia in a Pregnant Multipara C. Hecking, H. Schinzel (Mainz, DE)

S1-4 Recurrent Severe Pregnancy Complications with Thrombocytopenia and Hemolysis in Two Sisters T. Falter, I. Scharrer (Mainz, DE)

S1-5 Unprovoked Skin Bleeding: a Long Way to the Correct Diagnosis G. Colucci, L. Alberio (Berne, CH) Wednesday, February 12, 2014 Wednesday, 23 Scientific Programme – Wednesday, February 12, 2014

16.00 – 17.30 Forum SA3 Satellite Symposium German

Stago

Pre- and Postanalytic Aspects in Hemostasis Diagnostics. Interactive Examples: Clinician – Diagnostician

Chairs: D. Peetz (Berlin, DE) M. Spannagl (Munich, DE)

SA3–1 Preanalytics in Hemostasis Diagnostics P. Quehenberger (Vienna, AT)

SA3–2 Pitfalls in Hemostasis Diagnostics – Case Studies W.-M. Halbmayer (Vienna, AT)

SA3–3 Hemostasis diagnostics in pediatrics: Pecularities and clinical consequences W. Muntean (Graz, AT)

16.00 – 17.30 Geheime Ratstube SA4 Satellite Symposium

Grifols

Von Willebrand Factor-Disease and Therapy

Chair: J. Oldenburg (Bonn, DE)

SA4–1 Introduction J. Oldenburg (Bonn, DE)

SA4–2 The pathophysiology of von Willebrand Disease: Current Findings R. Schneppenheim (Hamburg, DE)

SA4–3 New insights into Type 3 von Willebrand Disease: 3WINTERS- IPS Project Update A. Federici (Milan, IT)

SA4–4 Secondary Prophylaxis in Willebrand Disease: PRO.WILL Study Interim Results F. Peyvandi (Milan, IT)

SA4–5 Importance of the von Willebrand Factor for Immune Tolerance Induction S. Lacroix-Desmazes (Paris, FR)

SA4–6 Summary and Discussion J. Oldenburg (Bonn, DE) Wednesday, February 12, 2014 Wednesday, 24 Scientific Programme – Wednesday, February 12, 2014

16.00 – 17.30 Gartensaal SA5 Satellite Symposium

BMS / Pfizer

From Head to Toe Prepared for a DOAC?

Chair: P. A. Kyrle (Vienna, AT)

SA5–1 Stroke Prevention in Atrial Fibrillation: Why Use a DOAC? J. Bauersachs (Hannover, DE)

SA5–2 Practical Considerations in Dealing with Direct Oral Anticoagulants N. Kucher (Berne, CH)

SA5–3 Treatment and Prophylaxis of Venous Thromboembolism: The AMPLIFY Program I. Pabinger (Vienna, AT)

16.00 – 17.30 Schatzkammersaal WG4 Working Group German

AG Erworbene Hämophilie

Chairs: A. Tiede (Hannover, DE) A. Huth-Kühne (Heidelberg, DE)

WG4-1 Erworbene Hämophilie: Übersicht über die GTH-Studie und ihre wichtigsten Ergebnisse A. Tiede, S. Werwitzke (Hannover, DE)

WG4-2 Rezidivierende erworbene Hämophilie: GTH-Studie und Konsequenzen für den Alltag* R. Klamroth (Berlin, DE), H. Eichler (Homburg, DE)

WG4-3 Blutungensmanagement: bringt die GTH-Studie etwas neues?* P. Knoebl (Vienna, AT), A. Huth-Kühne (Heidelberg, DE)

WG4-4 Anti-FVIII-Antikörper: diagnostischer und prognostische Wert von Subklassen und Affinität? C. Hofbauer, B. Reipert (Vienna, AT)

WG4-5 Anti-FVIII-Antikörper: Fortschritte im Epitop-Mapping C. Königs (Frankfurt, DE)

WG4-6 Diskussion Wednesday, February 12, 2014 Wednesday, 25 Scientific Programme – Wednesday, February 12, 2014

16.00 – 17.30 Radezky Appartment I WG5 Working Group German

Ständige Kommission Pädiatrie

17.45 – 19.15 Festsaal Opening Ceremony

Welcome Address by the Congress President Prof. Dr. Kurt Huber (Vienna, AT)

Bohuslav Martinu° Philharmonic Orchestra conducted by Dr. Norbert Pfafflmeyer Playing pieces of W.A. Mozart, J. Strauß (Son), Joseph Strauß, Franz von Suppé, J. Hellmesberger

Award Ceremony - Alexander-Schmidt-Award for excellent research studies in the field of haemostaseology - Award for young researchers I for excellent research in the field of thrombosis - Award for young researchers II for excellent research in the field of bleeding disorders - Erwin Deutsch Award of the GTH to promote outstanding scientists in the field of thrombosis and haemostasis research - Hans-Egli-Research Grant for young physicians and scientists for a 6-month research project on congenital bleeding disorders - Rudolf-Marx-Grant for young scientists from German-speaking countries Prof. Dr. Christoph Bode (Freiburg, DE), Prof. Dr. Kurt Huber (Vienna, AT) and Prof. Dr. Johann Wojta (Vienna, AT)

Alexander-Schmidt-Lecture M. Elvers (Düsseldorf, DE)

Opening of the Congress by the President of the GTH Prof. Dr. Christoph Bode (Freiburg, DE)

from 19.15 Exhibition Areas Welcome Reception

All participants of the 58th Annual Meeting of the GTH are heartily invited to visit the exhibition in order to meet colleagues, faculty members, abstract presenters, and industry for scientific exchange. Wednesday, February 12, 2014 Wednesday, 26 Scientific Programme – Thursday, February 13, 2014

09.00 – 10.00 Festsaal PL2 Plenary Session

Plenary Session II

Chairs: M. Geiger (Vienna, AT) P. A. Kyrle (Vienna, AT)

PL2-1 Tissue Factor – Signalling Beyond Coagulation A. Siegbahn (Uppsala, SE)

PL2-2 The Role of Tissue Factor Pathway Inhibitor in Atherothrombosis T. Hackeng (Maastricht, NL)

10.30 – 12.00 Festsaal S2 Scientific Symposium

State-of-the-Art

Joint Meeting with Acute Cardiovascular Care Association (ACCA) of the European Society of Cardiology (ESC)

New Issues in Acute Cardiac Care

Chairs: M. Lettino (Milan, IT) U. Zeymer (Ludwigshafen, DE)

S2-1 The Effect of Cooling After Cardiac Arrest on Coagulation and Haemostasis C. Hassager (Copenhagen, DK)

S2-2 Optimal Antithrombotic Treatment in Patients with Cardiogenic Shock Undergoing Left Ventricular Assistance U. Zeymer (Ludwigshafen, DE)

S2-3 News in Pre-Hospital Antithrombotic Strategies in ACS Patients P. Clemmensen (Copenhagen, DK)

S2-4 ACS, Antithrombotic Treatment and New Onset Thrombocytopenia K. Schrör (Düsseldorf, DE)

S2-5 Treatment of STEMI: Any Role for a Pharmaco-Invasive Strategy in Europe in 2014 S. Halvorsen (Oslo, NO) Thursday, February 13, 2014 Thursday, 27 Scientific Programme – Thursday, February 13, 2014

10.30 – 12.00 Kleiner Redoutensaal S3 Scientific Symposium

Joint Meeting with HUNGARY

Poor Inhibitory Response to Antiplatelet Drugs: Platelet Function Measurement and/or Stronger P2Y12-Inhibitors?

Chairs: R.G. Kiss (Budapest, HU) M.-C. Alessi (Marseille, FR)

S3-1 Does Aspirin Resistance Exist at all? L. Muszbek (Debrecen, HU)

S3-2 Platelet Function Measurement in Patients on Clopidogel: Update 2014 D. Aradi (Balatonfüred, HU)

S3-3 Should all ACS Patients Receive Prasugrel or Ticagrelor Instead of Clopidogrel? Pro: C. Bode (Freiburg, DE) Contra: K. Huber (Vienna, AT)

10.30 – 12.00 Forum S4 Scientific Symposium

Best Abstracts

CLINICAL RESEARCH

Chairs: J. Harenberg (Mannheim, DE) T. Weiss (Vienna, AT)

S4-1 Cellular Microparticles Captured from Malignant Effusions Show Concomitant Tissue Factor and Factor X Activity F. Gieseler, C. Plattfaut, H. Gamperl, T. Quecke, P. Winkelmann, A. Rody, H. Ungefroren (Lübeck, DE)

S4-2 Morphine Decreases Clopidogrel Concentrations and Effects: a Randomized, Double Blind, Placebo Controlled Trial E. Hobl, T. Stimpfl, J. Ebner, C. Schörgenhofer, U. Derhaschnig, R. Sunder-Plassmann, P. Jilma-Stohlawetz, C. Mannhalter, M. Posch, B. Jilma (Vienna, AT)

S4-3 Coronary NET Burden and DNase Activity are Predictors of Infarct Size After ST- elevation Acute Coronary Syndrome A. Mangold1, T. Scherz1, S. Alias1, T. Hofbauer1, A. Falkinger1, C. Adlbrecht1, K. Distelmaier1, 1 1 1 2 1 1 2 Thursday, February 13, 2014 Thursday, J. Jakowitsch , A. Panzenböck , M. Winter , K. Preissner , I. Lang ( Vienna, AT; Giessen, DE) 28 Scientific Programme – Thursday, February 13, 2014

10.30 – 12.00 Forum S4 Scientific Symposium

S4-4 Metamizol (Dipyrone) Prevents Platelet Inhibition by Aspirin in the Majority of Patients with Stable Cardiovascular Disease T. Hohlfeld, L. Stickelbruck, R. Werdehausen, P. Kienbaum, G. Pavlacovic, A. Schmitz (Düsseldorf, DE)

S4-5 In Patients with ECMO Diagnosis of an Acquired von Willebrand Syndrome (AVWS) at an Early Stage is Elementary for the Clinical Practice R. Schmidt1, L. Nakamura2, S. Rosenfelder2, J. Schelling2, J. Kalbhenn2, B. Zieger2 (1Stuttgart, DE; 2Freiburg, DE)

S4-6 Acquired Von Willebrand Factor Deficiency Caused By Left Ventricular Assist Devices is ADAMTS-13 and Platelet Dependent P. Jilma-Stohlawetz, H. Schima, P. Quehenberger, M. Stoiber, S. Schranz, B. Jilma (Vienna, AT)

10.30 – 12.00 Geheime Ratstube WS4 Workshop/Educational German

Symposium des Berufsverbandes der Deutschen Hämostaseologen

NOAC’S – Pro und Contra aus Sicht der Praxis

Chairs: J. Koscielny (Berlin, DE) U. Scholz (Leipzig, DE)

WS4-1 Pro R.B. Zotz (Düsseldorf, DE)

WS4-2 Contra C. Sucker (Berlin, DE) Thursday, February 13, 2014 Thursday, 29 Scientific Programme – Thursday, February 13, 2014

10.30 – 12.00 Gartensaal S5 Scientific Symposium

Joint Meeting with ITALY

Autoimmune Disease and Thrombosis

Chairs: A. D’Angelo (Milan, IT) C. Weber (Munich, DE)

S5-1 Update in APA Syndrome V. Pengo (Padova, IT)

S5-2 Autoimmunie Protein S Deficiency A. D’Angelo (Milan, IT)

S5-3 Anti-PF4/heparin IgG Antibodies are Potentially Associated with Graft Function Failure After Liver Transplantation T. Bakchoul1, K. Althaus1, G. Hron1, V. Aßfalg2, H. Zöllner1, N. Hüser2, A. Greinacher1; (1Greifswlad, DE; 2Munich, DE)

S5-4 Anti-idiotypic Designed-ankyrin Repeat Molecules (DARPins) Universally Neutralize Plasma-derived Autoantibodies in Acquired TTP Patients M. Schaller1, I. Sulzer1, M. Skowronska1, M. Vogel1, K. Kentouche2, B. Lämmle1, J.A. Kremer Hovinga1 (1Berne, CH; 2Jena, DE)

10.30 – 12.00 Schatzkammersaal S6 Scientific Symposium

Free Oral Presentations

Bleeding Disorders

Chairs: S. Eichinger-Hasenauer (Vienna, AT) A. Tiede (Hannover, DE)

S6-1 Situation of People with Haemophilia With Respect to Psychosocial Factors in Germany Compared to Other Western European Countries: HERO Study Results W. Kalnins1, C. Escuriola-Ettingshausen2, C. Königs3, W. Mondorf3 (1Hamburg, DE; 2Mörfelden-Walldorf, DE; 3Frankfurt, DE)

S6-2 Molecular Fusion of Two Tissue Factor Pathway Inhibitor (TFPI) Inhibitory Peptides Most Efficiently Improve Hemostasis in Hemophilia Models R. Hartmann1, T. Polakowski2, J. Brandstetter3, R. Pachlinger1, W. Kammlander1, E. Panholzer1, 1 2 1 1 1 2 3 Thursday, February 13, 2014 Thursday, C. Redl , F. Osterkamp , F. Scheiflinger , M. Dockal ( Vienna, AT; Berlin, DE; Salzburg, AT) 30 Scientific Programme – Thursday, February 13, 2014

10.30 – 12.00 Schatzkammersaal S6 Scientific Symposium

S6-3 Reversal of Anticoagulants Directly Inhibiting FXa or Thrombin (NOAC) by FEIBA Can be Monitored by Thrombin Generation Assay G. Schrenk, M. Schaedler, S. Peyrer-Heimstaett, H. Rottensteiner, F. Scheiflinger, P. Turecek (Vienna, AT)

S6-4 Plasma-derived Factor VIII, But Not Recombinant Factor VIII, Induces PF4 Release by Human Platelets and Thus Might Boost Blood Induced Joint Injury A. Bertling, M. Visser, J. Treffon, M. Fennen, M. Brodde, B. Kehrel (Münster, DE)

S6-5 Applicability of the ESC Guidelines on Management of Acute Coronary Syndromes to People With Haemophilia P. Staritz1, A. Huth-Kühne1, R. Klamroth2, N. Marquardt3, J. Oldenburg3, I. Pabinger4, G. Dolan5 (1Heidelberg, DE; 2Berlin-Friedrichshain, DE; 3Bonn, DE; 4Vienna, AT; 5UK)

S6-6 Novel Compound Heterozygous Mutations in Two Siblings with Bernard-Soulier Syndrome K. Sandrock-Lang1, R. Wentzell2, S. Santoso3, S. Gerisch1, A. Greinacher4, B. Zieger1 (1Freiburg, DE; 2Neuss, DE; 3Giessen, DE; 4Greifswald, DE)

12.30 – 14.00 Kleiner Redoutensaal SA6 Satellite Symposium

Novo Nordisk Pharma GmbH

Turoctocog alfa – a New Recombinant FVIII Resulting from Rational Product Development

Chair: B. Kemkes-Matthes (Giessen, DE)

SA6–1 Turoctocog Alfa – Reliability by Design R. Klamroth (Berlin, DE)

SA6–2 Clinical Results with Turoctocog Alfa – Review of the GuardianTM Trial Programme A. Tiede (Hannover, DE)

SA6–3 Home Treatment Under Physician’s Control Using Telemedicine (Smart Medication®) W. Mondorf (Frankfurt, DE) Thursday, February 13, 2014 Thursday, 31 Scientific Programme – Thursday, February 13, 2014

12.30 – 14.00 Forum SA7 Satellite Symposium German

Bayer HealthCare

Update Anticoagulation 2014

Chairs: K. Huber (Vienna, AT) W. Korte (St. Gallen, CH)

SA7–1 Introduction K. Huber (Vienna, AT)

SA7–2 Rivaroxaban for the Treatment of Venous Thromboembolism: The Pooled Analysis of EINSTEIN-DVT and EINSTEIN-PE R. Bauersachs (Darmstadt, DE)

SA7–3 A New Option for the Treatment of Acute Coronary Syndrome in Secondary Prevention – A New Kid on the Block C. Bode (Freiburg, DE)

SA7–4 Anticoagulation with NOACs – Where is our Attention Required? H. Lindhoff-Last (Frankfurt, DE)

SA7–5 Anticoagulation in Practice – Data of the Global Anticoagulant Registry in the FIELD (GARFIELD) S. Haas (Munich, DE)

SA7–6 Panel Discussion W. Korte (St. Gallen, CH)

SA7–7 Concluding Remarks W. Korte (St. Gallen, CH) Thursday, February 13, 2014 Thursday, 32 Scientific Programme – Thursday, February 13, 2014

12.30 – 14.00 Geheime Ratstube SA8 Satellite Symposium

Octapharma Immune Tolerance Induction in Haemophilia A: Between Standard Therapy and Individualized Concepts Chairs: W. Eberl (Braunschweig, DE) W. Kreuz (Mörfelden-Walldorf, DE) SA8–1 Immune Tolerance Induction in Haemophilia A: What Can We Learn from Current Systematic Studies? C. Escuriola-Ettingshausen (Mörfelden-Walldorf, DE) SA8–2 Novel Approaches for Tolerance Induction: Clinical Experience with Modifications of the Bonn Protocol S. Horneff (Bonn, DE) SA8–3 Practical Implications of ITI for Patients and Their Families – Support for Success K. Khair (London, GB)

12.30 – 14.00 Gartensaal SA9 Satellite Symposium

CSL Behring

Hemophilia Treatment in Changing Times Chairs: A. Huth-Kühne (Heidelberg, DE) R. Schneppenheim (Hamburg, DE) SA9–1 Do We Expect Alterations in Prophylaxis Treatment? J. Oldenburg (Bonn, DE) SA9–2 AFFINITY and PROLONG-9FP: Clinical study program update I. Pabinger (Vienna, AT) SA9–3 Innovation in Recombinant Coagulation Factors S. Schulte (Marburg, DE) SA9–4 Case Reports of Hemophilia Patients with Concomitant Diseases Cardiology: P. Staritz (Heidelberg, DE) Pediatrics: K. Kurnik (Munich, DE) Thursday, February 13, 2014 Thursday, 33 Scientific Programme – Thursday, February 13, 2014

14.30 – 15.45 Poster Area Poster Sessions 1-14

P1 Thrombosis I P2 Thrombosis II P3 Thrombosis III P4 Cardiovascular Disease I P5 Thrombosis and Haemostasis I P6 Thrombosis and Haemostasis II/Diabetes P7 Infection, Inflammation and Thrombosis P8 Leukocytes and Biomarkers P9 Novel Agents and Test Principles I P10 Novel Agents and Test Principles II P11 Platelet Function Testing/Platelet Aspects I P12 ADAMTS13/vWF I P13 ADAMTS13/vWF II P14 ADAMTS13/vWF III/Bleeding Disorders

Details please see pages 54-68.

16.00 – 17.30 Kleiner Redoutensaal SA10 Satellite Symposium

Daiichi Sankyo

Anticoagulation 2014: Where Are We Going?

Chairs: P. A. Kyrle (Vienna, AT) R. Bauersachs (Darmstadt, DE)

SA10–1 Laboratory Results and Their Proper Clinical Implementations W. Korte (St. Gallen, CH)

SA10–2 Limitations of Vitamine K Antagonists in Anticoagulation of Patients – Which Opportunities Appear from Direct Oral Anticoagulants? E. Lindhoff-Last (Frankfurt, DE)

SA10–3 Developments and Trends in the Therapy of Patients with Venous Thromboembolism S. Schellong (Dresden, DE)

SA10–4 Current and Emerging Options in the Anticoagulation of Patients with Atrial Fibrillation K. Huber (Vienna, AT) Thursday, February 13, 2014 Thursday, 34 Scientific Programme – Thursday, February 13, 2014

16.00 – 17.30 Forum SA11 Satellite Symposium

LEO Pharma

Research News in the Management of Venous Thromboembolism

Chair: F. Tatò (Munich, DE)

SA11–1 Initial Anticoagulation Therapy in Patients with Venous Thromboembolism and Impaired Renal Function: Results of an Observational Study T. Wilke (Wismar, DE)

SA11–2 Patients with Venous Thromboembolism in Clinical Practice – Between Ambition and Reality M. Wehling (Mannheim, DE)

SA11–3 UPDATE VTE Long-term Treatment in Cancer Patients G. Meyer (Paris, FR)

16.00 – 17.30 Geheime Ratstube SA12 Satellite Symposium

Biotest The Wild Type Factor VIII: Insights and Points of View Chairs: I. Pabinger (Vienna, AT) J. Oldenburg (Bonn, DE) SA12–1 The Wild Type FVIII and Prevention of Inhibitors J. Schüttrumpf (Dreieich, DE) SA12–2 The Evaluation of the Inhibitor Risk Factors in PUPs with Haemophilia A: The Results from the Competence Network Haemorrhagic Diatheses East R. Knöfler (Dresden, DE) SA12–3 Low Dose Immune Tolerance Induction: A Personal View C. Hay (Manchester, GB) SA12–4 High Dose Immune Tolerance Induction: A Personal View C. Male (Vienna, AUT) SA12–5 Preliminary Results of a Retrospective Cohort Study on Immune Tolerance Induction G. Auerswald (Bremen, DE) Thursday, February 13, 2014 Thursday, 35 Scientific Programme – Thursday, February 13, 2014

16.00 – 17.30 Gartensaal SA13 Satellite Symposium

Baxter Podium Discussion on: „Each Patient is Different – Future Needs for Optimal Treatment” Overview lecture: A. Reininger (Vienna, AT) SA13–1 „Is it All About Peaks and Troughs?” Individualized vs. Standardized Treatment SA13–2 Differences of Hemophilia A and Hemophilia B SA13–3 For an Optimized Patient Care, How Do Hemophilia Treatment Centers Look Like in the Future? Moderation: K. Voigt (Munich, DE) Discussion: C. Escuriola-Ettingshausen (Moerfelden, DE) A. Huth-Kuehne (Heidelberg, DE) R. Klamroth (Berlin, DE) A. Ehlers (Munich, DE)

17.45 – 19.00 Festsaal PL3 Plenary Session

Plenary Session III

Chairs: C. Kopp (Vienna, AT) U. Walter (Mainz, DE)

PL3-1 Thrombus Formation Beyond the Coagulation Cascade G. Lip (Birmingham, UK)

PL3-2 Biomarkers and Venous Thromboembolism I. Pabinger (Vienna, AT) Thursday, February 13, 2014 Thursday, 36 Scientific Programme – Friday, February 14, 2014

09.00 – 10.00 Festsaal PL4 Plenary Session

Plenary Session IV

Chairs: S. Eichinger-Hasenauer (Vienna, AT) K. Schrör (Düsselforf, DE)

PL4-1 New Approaches in Antiplatelet Therapy – Benefits and Risks M.-C. Alessi (Marseille, FR)

PL4-2 Anticoagulation in Secondary Prevention after ACS C. Bode (Freiburg, DE)

10.30 – 12.00 Festsaal S7 Scientific Symposium

State-of-the-Art

Reperfusion Strategies

Chairs: R. Scharf (Düsseldorf, DE) I. Seljeflot (Oslo, NO)

S7-1 STEMI Systems of Care – A World-wide Development F. Verheugt (Amsterdam, NL)

S7-2 DVT/Acute Pulmonary Embolism S. Konstandinides (Mainz, DE)

S7-3 Ischemic Stroke W. Lang (Vienna, AT) Friday, February 14, 2014 Friday, 37 Scientific Programme – Friday, February 14, 2014

10.30 – 12.00 Kleiner Redoutensaal S8 Scientific Symposium

Joint Meeting with DENMARK

Venous Thromboembolism

Chairs: A.-M. Bloch Münster (Aalborg, DK) E. Mahla (Graz, AT)

S8-1 Duration and Type of Thromboprophylaxis in the Era of Fast Track Orthopedic Surgery S.P. Johnsen (Aarhus, DK)

S8-2 Psychotropic Drug Prescription Risk Among Young Patients with Venous Thromboembolism: A Nationwide Population-Based Cohort Study A. Arbjerg Højen (Aalborg, DK)

S8-3 Changes of Coagulation Parameters at End of Treatment with VKA, Apixaban, Rivaroxaban or Dabigatran and Impact on Clinical Outcome After 12 Months S. Werth, L. Tittl, C. Köhler, S. Gehrisch, T. Stange, J. Beyer-Westendorf (Dresden, DE)

S8-4 Human Cofactor Independent Monoclonal Anticardiolipin Antibody Triggers Thrombus Formation in Vivo D. Manukyan, N. Müller-Calleja, S. Jäckel, K. Luchmann, C. Reinhardt, U. Walter, K. Lackner (Mainz, DE) Friday, February 14, 2014 Friday, 38 Scientific Programme – Friday, February 14, 2014

10.30 – 12.00 Forum S9 Scientific Symposium

Best Abstracts

BASIC RESEARCH

Chairs: S. Kastl (Vienna, AT) A. Siegbahn (Uppsala, SE)

S9-1 P2Y6 Deficiency Limits Vascular Inflammation and Atherosclerosis in Mice P. Stachon, A. Peikert, N. Michel, S. Hergeth, B. Dufner, D. Wolf, C. Bode, M. Idzko, A. Zirlik (Freiburg, DE)

S9-2 The VKDCF2 Causing Mutation Arg98Trp in hVKORC1 Gene Disrupts a Di-arginine ER Retention Motif K. Czogalla, A. Biswas, M. Watzka, J. Oldenburg (Bonn, DE)

S9-3 Visualization of VWF-FVIII-complex Formation by Single Molecule Imaging K. Bonazza, H. Rottensteiner, B. Seyfried, G. Schrenk, F. Scheiflinger, G. Allmaier, P. Turecek, G. Friedbacher (Vienna, AT)

S9-4 Cellular Requirements for the IgG Antibody Response Against the Platelet Factor 4/Heparin Complex in a Mouse Model of Heparin-induced Thrombocytopenia A. Schulze, K. Krauel, I. Jensch, C. Hackbarth, A. Greinacher, M. Hundt (Greifswald, DE)

S9-5 Low Molecular Weight Heparins Attenuate Cancer Progression by Blocking von Willebrand Factor Fiber Generation and Platelet Aggregation L. Görtz, A. Bauer, A. Desch, J. Suckau, V. Umansky, S. Schneider (Mannheim, DE)

S9-6 Resveratrol Suppresses PAI-1 Gene Expression in a Human in Vitro Model of Inflamed Adipose Tissue I. Zagotta1, E. Dimova2, J. Funke1, M. Wabitsch1, P. Fischer-Posovszky1, T. Kietzmann2 (1Ulm, DE; 2Oulu, FI) Friday, February 14, 2014 Friday, 39 Scientific Programme – Friday, February 14, 2014

10.30 – 12.00 Geheime Ratstube S10 Scientific Symposium

Hot Topic

Platelet Function Measurement and Genetic Profiling

Chairs: C. Bode (Freiburg, DE) M. Brodmann (Graz, IT)

S10-1 Platelet function assays: is there a role to predict adverse cardiovascular events in the PCI setting? P. A. Kyrle (Vienna, AT)

S10-2 PF Testing and Genetic Profiling in Clinical Practice: Status Quo J. Siller-Matula (Vienna, AT)

S10-3 Usefulness of PF Testing Beyond the Acute Phase of ACS Patients: Rationale and Design of the TROPICAL-ACS Study. D. Sibbing (Munich, DE)

S10-4 Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy C. Tersteeg1, S. De Maat1, S. De Meyer2, M. Smeets1, M. Roest1, R. Fijnheer1, K. Vanhoorelbeke2, P. De Groot1, C. Maas1 (1Utrecht, NL; 2Kortrijk, BE)

10.30 – 12.00 Gartensaal S11 Scientific Symposium

Joint Meeting with THE NETHERLANDS

Coagulation and Atherothrombosis

Chairs: T. Hackeng (Maastricht, NL) L. Badimon (Barcelona, ES)

S11-1 Vascular Calcification: the Price to Pay for Anticoagulation with Vitamin K-Antagonists L. Schurgers (Maastricht, NL)

S11-2 Coagulation Proteases in Cardiovascular Disease H. Ten Cate (Maastricht, NL)

S11-3 The Role of Thrombophilia in Arterial Thrombotic Disease S. Middeldorp (Amsterdam, NL) Friday, February 14, 2014 Friday, 40 Scientific Programme – Friday, February 14, 2014

10.30 – 12.00 Schatzkammersaal S12 Scientific Symposium

Free Oral Presentations

Laboratory Issues and Testing Principles

Chairs: G. Weigel (Innsbruck, AT) R.G. Kiss (Budapest, HU)

S12-1 Anticoagulant Hydrogels with Feedback Response to Different Steps of the Coagulation Cascade M. Maitz, J. Zitzmann, J. Hanke, C. Renneberg, M. Tsurkan, C. Werner (Dresden, DE)

S12-2 Points of Care (POC) Tests from Urine of Patients on Therapy with Dabigatran, Rivaroxaban, and Apixaban J. Harenberg1, S. Du1, S. Krämer1, C. Weiss1, R. Krämer2 (1Mannheim, DE; 2Heidelberg, DE)

S12-3 Measuring New Oral Anticoagulants in Thrombin Generation on Ceveron® alpha L. Wagner1, A. Olteanu2, N. Binder1 (1Vienna, AT; 2Sibiu, RO)

S12-4 TECHNOCLOT® Protein S - A new Simplified Assay for the Determination of Protein S Activity M. Leitner, M. Riha, N. Binder (Vienna, AT)

S12-5 Correlation Between Factor Xa Inhibitor Rivaroxaban, DRVVT and Thrombin Generation A. Siegemund1, U. Scholz1, T. Siegemund2 (1Leipzig, DE; 2La Jolla, US)

S12-6 Performance of Two New Functional Assays for the Rapid Detection of HIT- Antibodies N. Riteco1, S. Rochat1, S. Lee2, S. Jones2, L. Alberio1, G. Chan2 (1Berne, CH; 2Auckland, NZ) Friday, February 14, 2014 Friday, 41 Scientific Programme – Friday, February 14, 2014

12.30 – 14.00 Kleiner Redoutensaal SA14 Satellite Symposium

Novo Nordisk Pharma GmbH

Haemophilia and Pain – an Interdisciplinary Expert Panel Discussion

Chair: B. Zernikow (Datteln, DE)

SA14–1 Haemophilia and Pain – the Paediatric View (Case Reports) C. Escuriola-Ettingshausen (Frankfurt, DE)

SA14–2 Haemophilia and Pain – Adult Patients (Case Reports) S. Gottstein (Berlin, DE)

SA14–3 Haemophilia and Pain – the Physiotherapist’s Perspective M. Rosenthal (Duisburg, DE)

SA14–4 Evaluation of Cases by Pain Specialists and Discussion T. Wagner (Würselen, DE), B. Zernikow (Datteln, DE)

12.30 – 14.00 Forum SA15 Satellite Symposium

CSL Behring

All About Coagulation – Factor I to Factor XIII

Chairs: W. Eberl (Braunschweig, DE) C. Male (Vienna, AT)

SA15–1 EpiNine – an Epidemiological Hemophilia B Data Collection C. Bidlingmaier (Munich, DE)

SA15–2 Genetic Variances in Factor XIII Gene and their Potential Clinical Relevance H. Rott (Duisburg, DE)

SA15–3 A-, Hypo- and Dysfibrinogenemia in Pediatrics – Diagnosis and Therapy K. Beutel (Münster, DE)

SA15–4 Rare Factor Deficiencies in Gynecology U. Scholz (Leipzig, DE)

SA15–5 Treatment Options of Bleeding Complications with New Oral Anticoagulants W. A. Wuillemin (Luzern, CH) Friday, February 14, 2014 Friday, 42 Scientific Programme – Friday, February 14, 2014

12.30 – 14.00 Geheime Ratstube SA16 Satellite Symposium German/English

Bayer HealthCare

Change in Haemophilia Treatment – an Update

Chairs: A. Huth-Kühne (Heidelberg, DE) J. Oldenburg (Bonn, DE)

SA16–1 Developments in Prophylactic Treatment of Haemophilia I. Pabinger (Vienna, AT)

SA16–2 Applicability of the ESC Guidelines on Management of Acute Coronary Syndromes to People with Haemophilia – an Assessment G. Dolan (Nottingham, GB)

SA16–3 Telemedicine in Haemostaseology – Much More than a Patient’s Diary W. Mondorf (Frankfurt, DE)

12.30 – 14.00 Gartensaal SA17 Satellite Symposium

Boehringer Ingelheim

Oral Anticoagulation with Dabigatran

Chairs: K. Huber (Vienna, AT) U. Hoffmann (Munich, DE)

SA17–1 Introduction U. Hoffmann (Munich, DE)

SA17–2 Initial and Early Maintenance Therapy of VTE S. Schellong (Dresden, DE)

SA17–3 Long Term Maintenance Therapy of VTE R. Bauersachs (Darmstadt, DE)

SA17–4 Emergencies and Management of Bleeding H. Riess (Berlin, DE)

SA17–5 Dabigatran – Everydays Experience F. X. Roithinger (Mödling, AT)

SA17–6 Summary K. Huber (Vienna, AT) Friday, February 14, 2014 Friday, 43 Scientific Programme – Friday, February 14, 2014

14.15 – 16.15 Festsaal GTH General Assembly

GTH General Assembly

14.30 – 15.45 Poster Area Poster Sessions 15-28

P15 Bleeding Disorders I P16 Bleeding Disorders II P17 Bleeding Disorders III P18 Bleeding Disorders IV P19 Bleeding Disorders V P20 FXIII/Fibrinogen I P21 Fibrinogen II/Thrombin/Thrombocytopaenia P22 Platelet Aspects II P23 Platelet Aspects III P24 Antiplatelet Agents/Pharmacogenetics P25 Procoagulants P26 Coagulation P27 Omics and Microparticles P28 Platelet Aspects IV

Details please see pages 69-82. Friday, February 14, 2014 Friday, 44 Scientific Programme – Friday, February 14, 2014

16.30 – 18.00 Festsaal S13 Scientific Symposium

State-of-the-Art

Metabolic Syndrome, Diabetes and Thrombosis

Chairs: I. Seljeflot (Oslo, NO) T. Weiss (Vienna, AT)

S13-1 Metabolic Syndrome, Diabetes and Thrombosis L. Badimon (Barcelona, ES)

S13-2 Genetic Deficiency of TRAF-1 Attenuates Diet-induced Adipose Tissue Inflammation by Limiting the Pool of Circulating and Splenic Monocytes in Mice N. Michel, D. Wolf, P. Stachon, C. Bode, A. Zirlik (Freiburg, DE)

S13-3 Insight into Prothrombotic Profile of CAD Patients with T2DM by Evaluation of a New Platelet Activation Marker and Platelet Transcriptomic Profile L. Rossetti, M. Brambilla, P. Canzano, L. Piacentini, L. Castiglioni, D. Trabattoni, E. Bono, G. Teruzzi, G. Colombo, G. Marenzi, M. Rubino, A. Bartorelli, E. Tremoli, M. Camera (Milan, IT)

S13-4 The Gut Microbiota Regulates Small Intestinal Permeability and Obesity Development via Epithelial Neuropilin-1 N. Hörmann1, M. Bergentall2, S. Jäckel1, M. Simões-Brandao1, K. Kiouptsi1, F. Bäckhed2, C. Reinhardt1, U. Walter1 (1Mainz, DE; 2Göteborg, SE)

16.30 – 18.00 Kleiner Redoutensaal S14 Scientific Symposium

Österreichische Arbeitsgruppe für das Selbstmanagement der oralen Antikoagulation (ÖASA) / Arbeitsgemeinschaft Selbstkontrolle der Antikoagulation e.V. (ASA)

Is Patient Self-Management of Oral Anticoagulation Still „State-of-the-Art“?

Chairs: C. Sucker (Berlin, DE) T. Gary (Graz, AT)

S14-1 Anticoagulation with Coumarin Derivates and Patient Self-Management C. Sucker (Berlin, DE)

S14-2 Patient Self-Management and Patient Compliance in Austria V. Gartner (Vienna, AT)

S14-3 Patient Self-Management of Oral Anticoagulation in Times of NOAC’s/DOAC‘s

B. Dieplinger (Linz, AT) February 14, 2014 Friday, 45 Scientific Programme – Friday, February 14, 2014

16.30 – 18.00 Forum SA18 Satellite Symposium

Alexion

Complement and Coagulation: „Powerful Interaction“

Chair: E. Lindhoff-Last (Frankfurt, DE)

SA18–1 Introduction E. Lindhoff-Last (Frankfurt, DE)

SA18–2 Attention: PNH and Risk of Thrombosis A. Röth (Essen, DE)

SA18–3 TMA in Sight – Focus on aHUS M. Bommer (Ulm, DE)

SA18–4 Discussion and Summary

16.30 – 18.00 Geheime Ratstube S15 Scientific Symposium

LBI Experimental and Clinical Traumatology

Coagulopathy in Trauma (TIC) and Infection

Chairs: S. Bahrami (Vienna, AT) C. Binder (Vienna, AT)

S15-1 Fibrinogen – a Key Molecule in Diagnosis and Therapy in the Bleeding Trauma Patient C. Schlimp (Vienna, AT)

S15-2 Extracellular Nucleic Acids as Alarm- and Dangersignals in Trauma and Infection K. Preissner (Giessen, DE)

S15-3 Anti-PF4/Heparin IgM Antibodies are Likely an Innate Immune Response K. Krauel, B. Hietkamp, C. Hackbarth, A. Greinacher (Greifswald, DE)

S15-4 The T328K Mutation in Factor XII that Cause Angioedema Enhance its Susceptibility to Activation by Plasmin S. De Maat1, S. Van Dooremalen1, M. Mansi2, M. Cicardi2, P. De Groot1, C. Maas1 (1Utrecht, NL; 2Milan, IT) Friday, February 14, 2014 Friday, 46 Scientific Programme – Friday, February 14, 2014

16.30 – 18.00 Gartensaal SA19 Satellite Symposium

Pfizer Pharma GmbH

Optimising Haemophilia Therapy

Chair: A. Tiede (Hannover, DE) C. Male (Vienna, AT)

SA19–1 The Virologist’s Perspective – Considerations about pathogen safety of factor concentrates L. Gürtler (Munich, DE)

SA19–2 The Paediatrician’s Perspective – The best choice for each individual C. Bidlingmaier (Munich, DE)

SA19–3 The Lawyer’s Perspective – Criteria outside science G. Nitz (Berlin, DE)

16.30 – 18.00 Schatzkammersaal S16 Scientific Symposium

Free Oral Presentations

Leukocytes and Thrombosis

Chairs: J. Wojta (Vienna, AT) A. Greinacher (Greifswald, DE)

S16-1 Sphingosine-1-phosphate Enhances Thrombin-induced Migration of Human Monocytes via Transcriptional Upregulation of the Protease-activated Receptor-4 S. Mahajan-Thakur1, B. Sostman1, A. Fender2, K. Schrör2, B. Rauch1 (1Greifswald, DE; 2Düsseldorf, DE)

S16-2 Complement Mediated Formation of Procoagulatory Tissue Factor and Neutrophil Extracellular Traps on Biomaterials M. Fischer, C. Sperling, C. Werner (Dresden, DE)

S16-3 HNA-3a Antibodies Increase the Stiffness of Neutrophils – a Critical Parameter in the Pathogenesis of Transfusion-related Acute Lung Injury (TRALI) T. Berthold, M. Glaubitz, R. Palankar, S. Muschter, S. Gross, T. Bakchoul, M. Delcea, A. Greinacher (Greifswald, DE) Friday, February 14, 2014 Friday, 47 Scientific Programme – Friday, February 14, 2014

16.30 – 18.00 Schatzkammersaal S16 Scientific Symposium

S16-4 Platelet-monocyte Interaction Mediates Monocyte Extravasation and Foam Cell Formation S. Badrnya1, W. Schrottmaier1, J. Kral1, K. Yaiw2, O. Ovchinnikova2, I. Volf1, G. Schabbauer1, C. Söderberg-Nauclér2, A. Assinger1 (1Vienna, AT; 2Stockholm, SE)

S16-5 Human Cytomegalovirus-platelet Interaction Triggers TLR2-dependent Pro-Inflammatory and Pro Angiogenic Responses A. Assinger1, K. Yaiw2, J. Kral1, W. Schrottmaier1, L. Butler2, C. Söderberg-Nauclér2 (1Vienna, AT; 2Stockholm, SE)

S16-6 Human Monocyte Subsets Differently Express Tissue Factor K. Krychtiuk, M. Lenz, K. Huber, J. Wojta, G. Heinz, W. Speidl (Vienna, AT)

18.00 – 19.00 Festsaal PL5 Plenary Session

Plenary Session V

Chairs: C. Mannhalter (Vienna, AT) I. Seljeflot (Oslo, NO)

PL5-1 Microparticles – Basics from Measurement to Function L. Badimon (Barcelona, ES)

PL5-2 Microparticles – Clinical Implications C. Weber (Munich, DE) Friday, February 14, 2014 Friday, 48 Scientific Programme – Saturday, February 15, 2014

09.00 – 10.00 Festsaal PL6 Plenary Session

Plenary Session VI

Chairs: K. Preissner (Giessen, DE) W. Korte (St. Gallen, CH)

PL6-1 Inflammation, Immunity and Thrombosis C. Binder (Vienna, AT)

PL6-2 Thromboembolic Pulmonary Hypertension I. Lang (Vienna, AT)

10.30 – 12.00 Festsaal S17 Scientific Symposium

State-of-the-Art

Bridging, Bleeding and Transfusion

Chairs: B. Lämmle (Berne, CH/Mainz, DE) I. Lang (Vienna, AT)

S17-1 Bridging Therapy – What is Evidence, What is New? E. Mahla (Graz, AT)

S17-2 Antagonising Old and New Anticoagulants in Major Bleeding W. Korte (St. Gallen, CH)

S17-3 Anemia: Transfusion, EPO or Iron M. Spannagl (Munich, DE) Saturday, February 15, 2014 Saturday, 49 Scientific Programme – Saturday, February 15, 2014

10.30 – 12.00 Kleiner Redoutensaal S18 Scientific Symposium

Hot Topic

Oncology, Coagulation and Thrombosis

Chairs: C. Ay (Vienna, AT) A. Weltermann (Linz, AT)

S18-1 Tissue Factor in Cancer: New Molecular Insights and Therapeutic Implications H. Versteeg (Leiden, NL)

S18-2 Biomarkers Predictive of Venous Thromboembolism in Patients with Newly Diagnosed High Grade Gliomas J. Thaler, C. Ay, A. Kaider, E. Reitter, J. Haselböck, C. Zielinski, C. Marosi, I. Pabinger (Vienna, AT)

S18-3 Preliminary Results from the ONCOTEV Trial: Incidence and Risk Assessment of Venous Thromboembolism in Ambulatory Cancer Patients. C. Cella, M. Arcopinto, M. Sodano, L. Attademo, E. La Fata, C. Arturo, R. Moretto, A. Tufano, A.M. Cerbone, B. De Simone, D. Bruzzese, G. Di Minno (Naples, IT)

S18-4 The Role of ADAMTS-13 and von Willebrand factor in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study H. Obermeier, C. Ay, E. Reitter, S. Koder, P. Quehenberger, A. Kaider, C. Zielinski, I. Pabinger (Vienna, AT)

10.30 – 12.00 Forum S19 Scientific Symposium

Joint Meeting with Working Group on Thrombosis of the European Society of Cardiology (ESC)

Aging and Thrombosis

Chairs: J. Wojta (Vienna, AT) J. Morais (Leiria, PT)

S19-1 Developmental Onset of Cardiovascular Health and Disease T. Weiss (Vienna, AT)

S19-2 Inflammation, Metabolic Syndrome and Thrombosis in an Aging Population I. Seljeflot (Oslo, NO)

S19-3 Antithrombotic and Fibrinolytic Therapy in the Elderly S. Halvorsen (Oslo, NO) Saturday, February 15, 2014 Saturday, 50 Scientific Programme – Saturday, February 15, 2014

10.30 – 12.00 Forum S19 Scientific Symposium

S19-4 Association of the A/A-Genotype of F9 G32023A -Polymorphism (rs440051) with Age-Dependent Factor IX Activity and Risk of Venous Thromboembolism (VTE) R. Zotz1, D. Szafarczyk1, R. Scharf1, A. Gerhardt2 (1Düsseldorf, DE; 2Ulm, DE)

10.30 – 12.00 Geheime Ratstube S20 Scientific Symposium

Free Oral Presentations

Hot Topics – Miscellaneous

Chairs: M. Geiger (Vienna, AT) P. Quehenberger (Vienna, AT)

S20-1 Glycosylation of Autoantibodies: Insights into the Mechanisms of Immune Thrombocytopenia T. Bakchoul1, K. Walek2, G. Bein2, A. Krautwurst2, S. Santoso2, U. Sachs2 (1Greifswald, DE; 2Giessen, DE)

S20-2 Immunization Against Protein/Heparin Complexes in Pediatric Patients Undergoing Cardiac Surgery R. Jouni1, H. Zöllner1, J. Bagemühl1, U. Strobel1, A. Koster2, J. Amiral3, A. Greinacher1, T. Bakchoul1 (1Greifswald, DE; 2Berlin, DE; 3Neuville Sur Oise, FR)

S20-3 Occurrence of Venous or Arterial Thrombosis is Associated with Increased Mortality in Patients with the Lupus Anticoagulant J. Haselböck, F. Posch, S. Koder, P. Quehenberger, C. Zoghlami, C. Ay, I. Pabinger (Vienna, AT)

S20-4 TRPM7 Kinase Enhances Calcium Responses in Platelets and Plays an Important Role in Arterial Thrombosis and Stroke A. Braun1, W. Chen1, V. Chubanov2, M. Morowski1, P. Kraft1, S. Stritt1, S.K. Gotru1, H. Hermanns1, S. Gupta1, G. Stoll1, T. Gudermann2, B. Nieswandt1 (1Würzburg, DE; 2Munich, DE)

S20-5 Phosphorylation of CalDAG-GEFI by Protein Kinase A Prevents Conformational Change and Down Regulates Rap1b Activation H. Subramanian1, S. Gambaryan1, V. Nikolaev2, U. Walter3 (1Würzburg, DE; 2Göttingen, DE; 3Mainz, DE)

S20-6 IL-33 Induces Urokinase in Human Endothelial Cells - Possible Impact on Angiogenesis S. Stojkovic, C. Kaun, M. Heinz, K. Krychtiuk, C. Lemberger, R. De Martin, P. Petzelbauer,

I. Huk, K. Huber, J. Wojta, S. Demyanets (Vienna, AT) February 15, 2014 Saturday, 51 Scientific Programme – Saturday, February 15, 2014

10.30 – 12.00 Gartensaal S21 Scientific Symposium

Joint Meeting with the European Platelet Academy (EPA)

Platelets, Inflammation and Antiplatelet Drugs

Chairs: K. Schrör (Düsseldorf, DE) K. Huber (Vienna, AT)

S21-1 Introduction: Homotypic vs. Heterotypic Platelet Functions and Antiplatelet Drugs K. Schrör (Düsseldorf, DE)

S21-2 Platelet Aggregation Measurement(s) – Predictive Value vs. Other (inflammatory) Markers of CV – Risk D. Sibbing (Munich, DE)

S21-3 The Role of Platelet P2Y12 in Inflammation – Mechanistic Aspects M. Cattaneo (Milan, IT)

S21-4 Inflammation Markers, Changes by Antiplatelet Drugs and their Predictive Value in ACS Patients T. Geisler (Tübingen, DE)

S21-5 Platelet-derived Sphingosine-1-Phosphate Couples Platelet Activation with Inflammatory Reactions in Monocytes B. Rauch (Greifswald, DE) Saturday, February 15, 2014 Saturday, 52 Scientific Programme – Saturday, February 15, 2014

10.30 – 12.00 Schatzkammersaal S22 Scientific Symposium

Free Oral Presentations

ADAMTS13 and von Willebrand Factor

Chairs: J.A. Kremer-Hovinga (Berne, CH) M. Freynhofer (Vienna, AT)

S22-1 A Novel Platelet-free Shear Flow Assay to Investigate Shear-dependent Dysfunctionalities of VWF and ADAMTS13 M. Brehm, E. Kraus, K. Kraus, T. Obser, R. Schneppenheim (Hamburg, DE)

S22-2 Recombinant VWF Promotes Platelet Adhesion Under Shear Stress Dependent on its Multimer Size G. Schrenk, J. Schreiner, H. Gritsch, F. Scheiflinger, P. Turecek (Vienna, AT)

S22-3 Characterization of IgG anti-ADAMTS13 Autoantibodies Isolated from Patients with Acquired TTP and a Healthy Donor Pool R. Grillberger1, S. Skalicky1, G. Schrenk1, B. Plaimauer1, P. Knoebl1, L. Zheng2, P. Turecek1, H. Rottensteiner1, F. Scheiflinger1 (1Vienna, AT; 2Philadelphia, US)

S22-4 Acquired von Willebrand Syndrome in Patients on Extracorporeal Membrane Oxygenation? C. Heilmann, C. Benk, F. Beyersdorf, M. Baghai Arassi, B. Zieger, A. Schmutz, T. Wengenmayer, G. Trummer, U. Geisen (Freiburg, DE)

S22-5 Assessing New and Established Neurological and Cardiac Biomarkers in Acquired Thrombotic Thrombocytopenic Purpura (TTP) A. Peter1, M. Mansouri Taleghani1, N. Tiberti2, N. Turck2, N. Walter2, M. Schaller1, A. Leichtle1, J. Sanchez1, J.A. Kremer Hovinga1 (1Berne, CH; 2Geneva, CH) Saturday, February 15, 2014 Saturday, 53 Poster Sessions – Thursday, February 13, 2014

Poster Sessions 1-14 14:30 – 15:45 Poster authors of Poster Sessions 1-14 are kindly asked to mount their posters between Wednesday (February 12, 2014) 12:00 and Thursday (February 13, 2014) 10:00 latest. Posters need to be removed on Thursday (February 13, 2014) between 19:00–19:30.

P1 Thrombosis I

Chair: C. Male (Vienna, AT)

P1-1 Successful „Thrombolysis“ with Enoxaparin in Two Pediatric Patients Presenting with Intracardiac and Cerebral Thrombosis G. Wiegand, V. Icheva, M. Schoening, M. Hofbeck (Tübingen, DE)

P1-2 Potent Antithrombotic Effects of Two Specific Fxiia-inhibitors in a Rabbit Arteriovenous Shunt Model M. Fries1, J. Krupka1, F. May1, F. Kaspereit1, W. Krege1, V. Rayzman2, M.J. Wilson2, I. Pragst1, T. Weimer1, C. Panousis2, G. Dickneite1, M.W. Nolte1 (1Marburg, DE; 2Parkville, AU)

P1-3 Description of a Method to Choose a Conventional or Direct New Oral Anticoagulant S. Zolfaghari, J. Harenberg, C. Weiss (Mannheim, DE)

P1-4 The Prevalence of MTHFR C677T and Factor V Leiden G1691A and Prothrombin G20210A Polymorphisms in Stroke Patients from Costa Rica M. Solano, L. Salazar-Sanchez, M.J. Suarez Sanchez, J. Madrigla Sanchez (San Jose, CR)

P1-5 Inherited Thrombophilia in Costa Rican Women with Recurrent Miscarriage M.J. Suarez Sanchez, Y.T. Shih Chiou, L. Salazar-Sanchez, M. Solano (San Jose, CR)

P1-6 Plasminogen Activation and Extracellular Chaperones in the Clearance of Amorphous Protein Aggregates P. Constantinescu, M. Ranson, M. Wilson (Wollongong, AU)

P1-7 Exhaustive Investigation of the Coagulation Status of Patients with Low-flow Venous Malformations: The Effect of Anticoagulant Prophylaxis. F. Sampietro, V. Baraldini, G. Coppi, P. Della Valle, G. Riccipetitoni, E. Pattarini, A. D’Angelo (Milan, IT)

P1-8 Targeting Vascular Senescence Via Plant Derived Nf- b Inhibitors S. Khan, E. Awad, J. Breuss, A. Oszwald (Vienna, AT) Thursday, February 13, 2014 Thursday, 54 Poster Sessions – Thursday, February 13, 2014

P2 Thrombosis II

Chair: E. Lindhoff-Last (Frankfurt, DE)

P2-1 Clinical Phenotype of Recurrent SERPINC1 Mutations B. Luxembourg1, A. Pavlova2, E. Lindhoff-Last1, M. Spannagl3, F. Bergmann4, M. Krause5, S. Alesci6, E. Seifried1, C. Geisen1 (1Frankfurt, DE; 2Bonn, DE; 3Munich, DE; 4Hannover, DE; 5Wiesbaden, DE; 6Mannheim, DE)

P2-2 Long-term Treatment of Venous Thromboembolism (VTE) with Fondaparinux: A Novel Alternative to Vitamin-K-Antagonists (VKA) G. Worms, B. Krabbe, R. Bauersachs (Darmstadt, DE)

P2-3 Individual Absolute and Relative Risk (RR) of Pulmonary Embolism (PE) in Pregnancy and Puerperium R. Zotz1, R. Scharf1, A. Gerhardt2 (1Düsseldorf, DE; 2Ulm, DE)

P2-4 Burden of Disease in the German Patient Cohort of the International Registry for Paroxysmal Nocturnal Hemoglobinuria (PNH) A. Röth1, H. Schrezenmeier2, R. Leichtle2, W.E. Aulitzky3, M. Port4, J. Panse5, P. Borchmann6, U. Platzbecker7, T. Haferlach8, J. Dengler9, M. Klausmann10, T. Steinmetz6, M. Becker11, B. Schmidt12, M. Müller13, B. Höchsmann2 (1Essen, DE; 2Ulm, DE; 3Stuttgart, DE; 4Hannover, DE; 5Aachen, DE; 6Cologne, DE; 7Dresden, DE; 8Munich, DE; 9Heidelberg, DE; 10Aschaffenburg, DE; 11Porta Westfalica, DE; 12Munich Pasing, DE; 13Offenburg, DE)

P2-5 Chronic Kidney Disease in Patients with Cancer and its Association with Risk of Venous Thromboembolism O. Königsbrügge, F. Lötsch, C. Zielinski, I. Pabinger, C. Ay (Vienna, AT)

P2-6 Right Ventricular Dysfunction in Hemodynamically Stable Patients with Acute Pulmonary Embolism K. Keller, J. Beule, A. Schulz, M. Coldewey, W. Dippold, J. Balzer (Mainz, DE)

P2-7 Treatment of Acute VTE with Rivaroxaban – Results of the Prospective Dresden NOAC Registry (NCT01588119) S. Werth, F. Ebertz, V. Gelbricht, K. Förster, C. Köhler, L. Tittl, J. Beyer-Westendorf (Dresden, DE)

P2-8 Oral Anticoagulation in Pulmonary Embolism and Deep Vein Thrombosis – Results from a Setting in Regular Medical Care K. Keller, M. Foebel, J. Prochaska, M. Coldewey, S. Goebel, A. Ullmann, H. Lamparter, L. Ariza, T. Munzel, P. Wild (Mainz, DE)

P2-9 Gender-specific Differences in Heamo-dynamically Stable Patients with Acute Pulmonary Embolism K. Keller, J. Beule, A. Schulz, M. Coldewey, W. Dippold, J. Balzer (Mainz, DE) Thursday, February 13, 2014 Thursday, 55 Poster Sessions – Thursday, February 13, 2014

P2-10 Effect of the Dual Thrombin/Fxa Inhibitor, SATI, in a Model of Microthrombosis in Rats M. Lopez1, S. Heitmeier2, V. Laux2, G. Nowak3 (1Caracas, VE; 2Wuppertal, DE; 3Jena, DE)

P3 Thrombosis III

Chair: A. Siegbahn (Uppsala, SE)

P3-1 Thrombophilic Factors Associated with Venous Sinus Thrombosis in Costa Rican Patients, First Report L. Salazar-Sanchez, M. Carvajal, P. Alexander, D. Guzman; (San Jose, CR)

P3-2 Deep Vein Thrombosis - Have You Considered May-Thurner Syndrome? N. Aveyard, T. Dobbs (Oxford, UK)

P3-3 Management of High Risk Pregnancies Due to Antithrombin Deficiency R. Fischer, K. Heidinger, M. Alrifai, B. Kempkes Matthes (Gießen, DE)

P3-4 Antithrombin Deficiency: Optimal Diagnostics for a Save Therapy R. Schobeß, A. Siegemund, I. Große, U. Scholz (Leipzig, DE)

P3-5 Importance of Thrombophilia Screening and Anticoagulation in Patients with Ocular Venous Thrombosis M. Alrifai, K. Heidinger, R. Fischer, C. Kelm, B. Kemkes-Matthes (Giessen, DE)

P3-6 Catheter Directed Ultrasound Accelerated Thrombolysis (EKOS)in Adolescents with Deep Vein Thrombosis Caused by May Thurner Syndrome: 2 Case Reports M. Olivieri, F. Hoffmann, K. Reiter, C. Bidlingmaier, P. Kuhlencordt, M. Treitl, K. Kurnik (Munich, DE )

P3-7 Location of the DVT in Patients with Inherited Thrombophilia N. Pirtskhelani, L. Makhaldiani, N. Kochiashvili, N. Pargalava, E. Gaprindashvili, K. Kartvelishvili (Tbilisi, GE)

P3-8 Case Report: Challenges in Functional Thrombophilia Screening P. Würtinger1, L. Loacker1, A. Griesmacher1, C. Mannhalter2, G. Weigel1 (1Innsbruck, AT; 2Vienna, AT)

P3-9 Thrombosis Involving the Inferior Vena Cava and Malignant Disease B. Linnemann, C. Kraft, G. Schüttfort, Y. Weil, V. Tirneci, A. Kasper, B. Haberichter, J. Schwonberg, M. Schindewolf, E. Lindhoff-Last (Frankfurt, DE)

P3-10 Prevalence of Established Risk Factors for Venous Thromboembolism According to Age B. Linnemann, L. Weingarz, J. Schwonberg, M. Schindewolf, A. Weber, E. Herrmann, E. Lindhoff-Last (Frankfurt, DE) Thursday, February 13, 2014 Thursday, 56 Poster Sessions – Thursday, February 13, 2014

P4 Cardiovascular Disease I

Chair: T. Weiss (Vienna, AT)

P4-1 Local Macrophage Proliferation Dominates Macrophage Accumulation in Advanced Atherosclerosis I. Hilgendorf1, C.S. Robbins1, G.F. Weber1, I. Theurl1, Y. Iwamoto1, L. Gerhardt1, J. Figueiredo1, R. Gorbatov1, G. Sukhova1, D. Smyth2, C. Zavitz2, E. Shikatani2, M. Parsons2, M. Husain2, N. Van Rooijen3, P. Libby1, M. Nahrendorf1, R. Weissleder1, F. Swirski1 (1Boston, US; 2Toronto, CA; 3Amsterdam, NL)

P4-2 The Impact of Uric Acid on Long-term Mortality in Patients with Asymptomatic Carotid Artery Disease F. Mayer1, M. Hoke2, M. Schillinger2, E. Minar2, R. Koppensteiner2, G. Siegert1, T. Chavakis1, C. Mannhalter2 (1Dresden, DE; 2Vienna, AT)

P4-3 Platelet Immunology in ACS - Toll Like Receptor 2 (TLR-2) is Significantly Increased in Platelets from Patients with Acute Coronary Syndrome. M. Albrecht1, D. Duerschmied1, C. Colberg1, A. Zirlik1, K. Peter2, C. Bode1, I. Ahrens1 (1Freiburg, DE; 2Melbourne, AU)

P4-4 Acute inhibition of RhoA Prior to Reperfusion Improves Cardiac Healing Post-Myocardial Infarction G. Vilahur, L. Casani, E. Peña, O. Juan-Babot, G. Mendieta, J. Crespo, L. Badimon (Barcelona, ES)

P4-5 Real Life Efficacy and Safety of Rivaroxaban for Stroke Prevention in Atrial Fibrillation: Updated Results of the Dresden NOAC Registry (NCT01588119) F. Ebertz, V. Gelbricht, K. Förster, C. Köhler, S. Werth, L. Tittl, J. Beyer-Westendorf (Dresden, DE)

P4-6 Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation: Updated Results of the Dresden NOAC Registry (NCT01588119) C. Köhler, F. Ebertz, V. Gelbricht, K. Förster, S. Werth, L. Tittl, J. Beyer-Westendorf (Dresden, DE)

P4-7 Extracellular RNA Provokes Cardiac Damage During Ischemia/Reperfusion Injury: Protection by RNase1 H. Cabrera-Fuentes1, M. Ruiz-Meana2, S. Simsekyilmaz3, S. Kostin4, J. Inserte2, M. Saffarzadeh1, V. Vijayan1, I. Barba2, S. Fischer1, G. Lochnit1, O. Ilinskaya1, E. Baumgart-Vogt1, A. Böning1, E. Liehn3, D. Hausenloy5, D. Garcia-Dorado2, K. Schlüter1, K. Preissner1 (1Giessen, DE; 2Barcelona, ES; 3Aachen, DE; 4Bad Nauheim, DE; 5London, UK)

P4-8 Real Life Efficacy and Safety of Apixaban for Stroke Prevention in Atrial Fibrillation: Updated Results of the Prospective NOAC Registry (NCT01588119) F. Ebertz, V. Gelbricht, K. Förster, C. Köhler, S. Werth, L. Tittl, J. Beyer-Westendorf (Dresden, DE) Thursday, February 13, 2014 Thursday, 57 Poster Sessions – Thursday, February 13, 2014

P5 Thrombosis and Haemostasis I

Chair: D. Aradi (Balatonfüred, HU)

P5-1 Methylated Plasminogen Activator Inhibitor-1 Gene Sequences in Serum DNA of Patients with Prostate Cancer M. Menschikowski, B. Nacke, A. Hagelgans, S. Fuessel, M. Wirth, G. Siegert (Dresden, DE)

P5-2 Vascular Calcification: the Price to Pay for Anticoagulation Therapy with Vitamin K-Antagonists L. Schurgers, M. Chatrou, T. Hackeng, C. Reutelingsperger (Maastricht, NL)

P5-3 Presence of Circulating Anti-ADAMTS13 Specific B-cells Following Acute Acquired Thrombotic Thrombocytopenic Purpura (Attp) M. Skowronska, J.A. Kremer Hovinga, I. Sulzer, B. Lämmle, M. Schaller (Berne, CH)

P5-4 Parenteral Treprostinil Leads to a Shift in the Myeloid to Plasmacytoid Dendritic Cell Ratio T. Hofbauer, A. Mangold, T. Scherz, R. Sadushi-Kolici, I. Lang (Vienna, AT)

P5-5 Opposing function of activin A: anti-lymphangiogenic but pro-metastatic in a Melanoma Mouse Model M. Heinz, H. Leb Niederleithner, E. Puujalka, A. Soler-Cardona, H. Pehamberger, R. Loewe, P. Petzelbauer (Vienna, AT)

P5-6 A High Essen Stroke Risk Score is Associated with a High Risk for Critical Limb Ischemia in Peripheral Arterial Occlusive Disease Patients T. Gary, K. Belaj, H. Froehlich, F. Hafner, P. Eller, M. Brodmann (Graz, AT)

P5-7 Parenteral Treprostinil Inhibits the Recruitment of Circulating Fibrocytes and Enhances BMPRII Expression T. Hofbauer, A. Mangold, T. Scherz, R. Sadushi-Kolici, I. Lang (Vienna, AT)

P5-8 Folate Exchange Factors in Nenets Population N. Vorobyeva, N. Belova, P. Lavrinov (Arkhangelsk, RU)

P5-9 Elevated Blood Urea Nitrogen is Associated with CLI in PAOD Patients K. Belaj, G. Schilcher, F. Hafner, P. Eller, G. Hackl, M. Brodmann, T. Gary (Graz, AT)

P5-10 Smoking-induced Alterations of the Coagulation System – the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study G. Delgado1, R. Siekmeier2, T. Grammer1, B. Boehm3, W. März1, M. Kleber1 (1Mannheim, DE; 2Bonn, DE; 3Ulm, DE) Thursday, February 13, 2014 Thursday, 58 Poster Sessions – Thursday, February 13, 2014

P6 Thrombosis and Haemostasis II, Diabetes

Chair: L. Badimon (Barcelona, ES)

P6-1 Management of Pregnant Patients with Antithrombin Deficiency M. Von Depka, S. Döpke, A. Henkel-Klene, C. Wermes, M. Ekhlasi-Hundrieser, C. Detering (Hannover, DE)

P6-2 Von Willebrand Factor Production by Endothelial Cells is Affected by C Reactive Protein Via NF-B. M. Shahidi (Tehran, IR)

P6-3 Lack of Platelet-derived Serotonin Limits Leukocyte Recruitment into Adipose Tissue in Diet-induced Obesity in Mice S. Schmitt, D. Wolf, N. Michel, M. Mauler, C. Bode, A. Zirlik, D. Duerschmied (Freiburg, DE)

P6-4 Individual Absolute and Relative Risk (RR) of First Venous Thromboembolism (VTE) in Pregnancy and Puerperium A. Gerhardt1, R. Scharf2, R. Zotz2 (1Ulm, DE; 2Düsseldorf, DE)

P6-5 Perioperative Management in a Paediatric Patient with Protein S Deficiency C. Schindera1, R. Zuker2, N. Von Der Weid1, S. Williams2 (1Basel, CH; 2Toronto, CA)

P6-6 Clotting during Extracorporeal Circulation in Heart Surgery Due to Incorrect Production of Surgical Woven Fabric U. Seyfert (Saarbrücken, DE)

P6-7 Recurrent Cerebral Ischaemia in a Pregnant Woman with PFO and Thrombophilia C. Hecking, M. Hendelmeier, S. Von Bardeleben, K. Gröschel, H. Schinzel (Mainz, DE)

P6-8 ACE I/D, MTHFR C677T, CCR5 d32 Gen and its Association with Diabetic Nephropathy in Urban Areas of Costa Rica, Nicaragua and Mexico L. Salazar-Sanchez1, C. Boza Flores1, N. Valadez González2, E. Paredes3, L. Ligia Vera Gamboa2, L. Calvo Flores1, Y. Yondra Vanegas Padilla3, J.J. Madrigal Sánchez1, P. Pedro González Martínez2 (1San Jose, CR; 2Yucatan, MX; 3Leon, NI)

P6-9 LMWH Treatment During Pregnancy in Women with History of Unexplained Miscarriage R. Fischer1, M. Alrifai1, K. Heidinger1, C. Kelm1, A. Kirsch-Altena1, R. Mahnel2, C. Mondorf2, W. Mondorf2, B. Kemkes-Matthes1 (1Giessen, DE; 2Frankfurt, DE)

P6-10 Gut Microbes Augment Apelin Expression in Intestinal Microvascular Endothelial Cells Via Tlr Signaling I. Brandao, N. Hörmann, C. Reinhardt (Mainz, DE) Thursday, February 13, 2014 Thursday, 59 Poster Sessions – Thursday, February 13, 2014

P7 Infection, Inflammation and Thrombosis

Chair: S. Kastl (Vienna, AT)

P7-1 Inflammatory and Hemostatic Markers in Sepsis Patients with Non-Overt and Overt Disseminated Intravascular Coagulation D. Hoppensteadt1, K. Tsuruta2, I. Kaul2, Y. Osawa2, J. Hirman3, J. Fareed1 (1Maywood, US; 2Waltham, US; 3Woodinville, US)

P7-2 Glutathione Inhibits Panton Valentine Leukocidin-induced Neutrophil-mediated Platelet Activation by Preventing Neutrophil Perforation A. Bertling1, S. Niemann1, B. Schlott2, C. Heilmann1, G. Peters1, B. Löffler1, B. Kehrel1 (1Münster, DE; 2Jena, DE)

P7-3 Biomonitoring of the Innate Microbicidal Capacity by Platelets V. Stoldt, R. Scharf (Düsseldorf, DE)

P7-4 Platelets in host defense - Increased susceptibility to subcutaneous S. aureus infection in Nbeal2-Deficient Mice A. Bertling1, S. Niemann1, C. Deppermann2, B. Nieswandt2, B. Löffler1, B. Kehrel1 ( 1Münster, DE; 2Würzburg, DE)

P7-5 Treatment of Infection-Associated Purpura Fulminans with Protein C Zymogen is Associated with a High Survival Rate P. Knöbl, P. Schellongowski, T. Staudinger, C. Scheibenpflug (Vienna, AT)

P7-6 Splenectomy Delays Thrombus Resolution M. Frey1, S. Alias1, M. Winter1, B. Redwan2, G. Stübiger1, A. Panzenboeck1, A. Alimohammadi1, D. Bonderman1, J. Jakowitsch1, H. Bergmeister1, V. Bochkov1, K. Preissner3, I. Lang1 (1Vienna, AT; 2Münster, DE; 3Giessen, DE)

P7-7 Alterations of Blood Coagulation in Early Stage Experimental Malaria J. Riedl1, B. Mordmueller2, S. Koder1, M. Ramharter1, I. Pabinger1, C. Ay1 (1Vienna, AT; 2Tübingen, DE)

P7-8 Insights into the Onset of Acute Vascular Rejection Following Xenotransplantation in a Micro Fluidic Flow-Chamber System D. Rataj1, S. Werwitzke1, M. Winkler1, W. Ramackers1, H. Niemann2, J. Abicht3, E. Wolf3, A. Tiede1 (1Hannover, DE; 2Neustadt, DE; 3Munich, DE)

P7-9 The Complexity of the Endothelial-cell Specific ERG-family of Transcription Factors N. Malkani, B. Hoesel, J. Schmid (Vienna, AT)

P7-10 Nigella sativa oil inhibits NF-kB Signaling In Vitro and in Two Murine In Vivo Models E. Awad, J. Breuss (Vienna, AT) Thursday, February 13, 2014 Thursday, 60 Poster Sessions – Thursday, February 13, 2014

P8 Leukocytes and Biomarkers

Chair: I. Lang (Vienna, AT)

P8-1 Developmental Endothelial Locus-1 (Del-1): a Potential Inhibitor of Factor V-dependent Coagulation Acceleration G. Siegert, I. Mitroulis, T. Chavakis (Dresden, DE)

P8-2 Acquired ADAMTS-13 Deficiency in Patients with Severe Thrombotic Microangiopathie After Hematopoietic Stem Cell Transplantation M. Koldehoff, D. Beelen (Essen, DE)

P8-3 Quantification of Prothrombin Fragment 1+2 (F1+2) in Human Citrated Plasma Based on LOCI Technology * M. Ehm, M. Pfeiff, L. Feddersen, V. Smith, H. Althaus, B. Fischer, M. Hahn, H. Schwarz, S. Stephan, N. Zander (Marburg, DE)

P8-4 Validation of new Chemiluminescent Method for determination of Anti- cardiolipin Antibodies in Antiphospholipid Syndrome Diagnosis D. Janek1, L. Slavik2, J. Ulehlova2, J. Wijová1, V. Krcova2, A. Hlusi1, J. Prochazkova2 (1Karviná Ráj, CZ; 2Olomouc, CZ)

P8-5 The Role of Tissue Factor in Activation of Coagulation System at Pregnancy Complications L. Slavik, J. Prochazkova, J. Ulehlova, M. Prochazka, P. Polak, M. Novak, R. Pilka, M. Lubusky (Olomouc, CZ)

P8-6 Circulating Immune Cells after Splenectomy M. Frey, M. Gerges, C. Tufaro, V. Seidl, D. Bonderman, I. Schwarzinger, K. Lechner, I. Lang (Vienna, AT)

P8-7 Comparison of Local and Systemic Inflammatory, Fibrinolytic and Hemostatic Parameters in Patients with Varicose Veins M. Jezovnik1, D. Syed2, S. Tetik1, D. Hoppensteadt2, P. Paredos1, J. Fareed2 (1Ljubljana, SI; 2Maywood, US)

P8-8 New High Sensitive LOCI D-dimer Method for the Detection of Very Low Concentrations in Human Citrated Plasma * D. Kraul, O. Pohlack-Marsch, P. Vesper, U. Gross, C. Schelp, M. Ehm (Marburg, DE)

P8-9 Gut Microbial Communities Impact on von Willebrand Factor Multimer Levels M. Lillich, S. Jäckel, K. Alber, N. Hörmann, U. Walter, C. Reinhardt (Mainz, DE)

P8-10 The Intestinal Microbiota Affects Intestinal Coagulation Factor Synthesis and Arterial Thrombus Formation E. Wilms, A. Khandagale, N. Hörmann, S. Jäckel, K.J. Lackner, U. Walter, C. Reinhardt (Mainz, DE) Thursday, February 13, 2014 Thursday, 61 Poster Sessions – Thursday, February 13, 2014

P9 Novel Agents and Test Principles I

Chair: J. Harenberg (Mannheim, DE)

P9-1 Comparison of Calibrated Chromogenic Anti-Xa Assay (DiXa) and Routinely Used Anti-Xa Assay for LMWH as Orientating Test for Rivaroxaban (RXA) E. Wimmer, J. Seier, G. Wallner-Holter, M. Gruenberger, P. Rechberger, A. Haushofer (Wels, AT)

P9-2 Determination of Direct Oral Factor Xa and Thrombin Inhibitors from Serum Samples of Patients on Treatment J. Harenberg1, S. Krämer1, S. Du1, C. Weiss1, R. Krämer2 (1Mannheim, DE; 2Heidelberg, DE)

P9-3 Measurement of Rivaroxaban from Serum Samples of Patients on Treatment S. Krämer1, J. Harenberg1, S. Du1, R. Krämer2, C. Weiss1 (1Mannheim, DE; 2Heidelberg, DE)

P9-4 Routine Monitoring of Argatroban and Lepirudin by aPTT is not Predictive of Direct Thrombin Inhibitor Levels in Critically Ill Patients H. Seidel, T. Treschan, P. Kienbaum, M. Beiderlinden, S. Rehder, R. Scharf (Düsseldorf, DE)

P9-5 Analysis of Apixaban in Serum and Urine Samples of Patients with Atrial Fibrilation J. Harenberg1, S. Du1, S. Krämer1, R. Krämer2, C. Weiss1 (1Mannheim, DE; 2Heidelberg, DE)

P9-6 Potency Assignment and Measurement of Recombinant FIX Activity in Human Plasma – Impact of aPTT Reagents on the 1-stage Clotting Assay H. Gritsch, S. Romeder-Finger, F. Scheiflinger, P. Turecek (Vienna, AT)

P9-7 Studies of Purified Poloxamer 188 Using Clot Based and Viscoelastic Measurements of Coagulation D. Hoppensteadt1, O. Iqbal1, S. Abro1, M. Emanuele2, J. Fareed1 (1Maywood, US; 2San Diego, US)

P9-8 Measurement of the New Oral Anticoagulants L. Wagner, M. Leitner, N. Binder (Vienna, AT)

P9-9 A new Control Material for Prothrombin Time for Point-of-care Instruments Detects Batch Variations in Test Strips T. Lindahl, L. Faxälv, K. Gustafsson (Linköping, SE)

P9-10 Different Whole Blood Fibrin Test Results in Thrombelastography and Thromboelastometry – Which One is True? F. Prüller, R. Raggam, E. Mahla, M. Truschnig, W. Toller (Graz, AT) Thursday, February 13, 2014 Thursday, 62 Poster Sessions – Thursday, February 13, 2014

P10 Novel Agents and Test Principles II

Chair: M. Spannagl (Munich, DE)

P10-1 Evaluation of Concentrations of Dabigatran on Various Coagulation and Chromogenic Assays from Plasma Samples of Patients on Treatment S. Du1, J. Harenberg1, S. Krämer1, C. Weiss1, R. Krämer2 (1Mannheim, DE; 2Heidelberg, DE)

P10-2 Defibrotide Interaction with Newer Oral Anticoagulant and Antiplatelet Drugs J. Fareed, D. Hoppensteadt, M. Moorman (Maywood, US)

P10-3 Clot Waveform Analysis in Patients with Haemophilia A A. Siegemund1, U. Scholz1, R. Schobeß1, T. Siegemund2 (1Leipzig, DE; 2La Jolla, US)

P10-4 Effect of Recombinant Factor VIIa BAY 86-6150 on Clot Formation Kinetics A. Siegemund1, N. Adam1, R. Schobeß1, U. Scholz1, T. Siegemund2 (1Leipzig, DE; 2La Jolla, US)

P10-5 One Year Experience with Clot Waveform Analysis A. Siegemund1, R. Schobeß1, U. Scholz1, T. Siegemund2 (1Leipzig, DE; 2La Jolla, US)

P10-6 Fibrinogen Protects Activated Factor XIII from Early Inactivation in Human Plasma N. Hamedani, R. Krammer, J. Müller, H. Rühl, J. Oldenburg, B. Pötzsch (Bonn, DE)

P10-7 Physiological Thrombophilia Screening Platform: a Single Test Method – from Global Screening up to Differentiation and Quantification of Unique Defects K. Schubart1, A. Siegemund2, T. Schulz1, S. Karasch1 (1Berlin, DE; 2Leipzig, DE)

P10-8 The Reliability of Automated Morphometric Measurements of Platelet Shape S. Grieger1, M. Kraus2, E.F. Strasser3, H. Neeb1 (1Remagen,DE; 2Grünwald, DE; 3Erlangen, DE)

P10-9 Novel Peptides to Improve Endothelial Function K. Schossleitner, A. Habertheuer, D. Wiedemann, P. Petzelbauer (Vienna, AT)

P10-10 Effect of Apixaban on Common Coagulation Analyses A. Hillarp1, K. Gustafsson2, F. Baghaei3, I. Fagerberg Blixter3, M. Berndtsson4, K. Strandberg1, T. Lindahl2 (1Malmo, SE; 2Linkoping, SE; 3Gothenburg, SE; 4Stockholm, SE) Thursday, February 13, 2014 Thursday, 63 Poster Sessions – Thursday, February 13, 2014

P11 Platelet Function Testing, Platelet Aspects I

Chair: G. Weigel (Innsbruck, AT)

P11-1 Von Willbrand Factor Assay in Patients with Aortic Valve Stenosis: vWF Ristocetin Cofactor Activity and Antigen Versus Impedence Aggregometry. C. Buonomo, V. Ajello, A. Farinaccio, P. De Vico, D. Colella (Rome, IT)

P11-2 Evaluation of the New Device ROTEM®Platelet T. Lang, M. Tollnick, R. Markus (Hohne, DE)

P11-3 Assessment of a Novel Synthetic Collagen Reagent by Platelet Aggregometry W. Jeske, V. Escalante, J. Walenga, M. Bakhos (Maywood, US)

P11-4 Automated Methods* for the Measurement of Platelet VWF and Platelet Factor XIII in Platelet Rich Plasma J. Patzke (Marburg, DE)

P11-5 Citrate-induced Pseudothrombocytopenia Misleading to the Diagnosis of Thrombocytopathy: A Case Report C. Boogen1, G. Kappert2 (1Cologne, DE; 2Duisburg, DE)

P11-6 Influence of the New Anticoagulants on POC and Platelet Function Tests T. Eller1, J. Busse2, C. Brandenburger2, A. Hohbein2, M. Dittrich3, T. Flieder2, S. Alban4, C. Knabbe2, I. Birschmann2 (1Minden, DE; 2Bad Oeynhausen, DE; 3Würzburg, DE; 4Kiel, DE)

P11-7 Monitoring of Anti-platelet Therapy: A Comparison of Methods C. Kirchmaier, D. Pillitteri, A. Pilgrimm-Thorp, M. Krause, T. Behrendt, T. Scholz (Wiesbaden, DE)

P11-8 Reticulated Platelets as Index of Platelet Turnover Predict Outcome after Coronary Intervention M.K. Freynhofer, L. Yukhanyan, I. Brozovic, V. Bruno, M. Rohla, F.S. Egger, S. Gruber, K. Leibl, T. Weiss, W. Hübl, M. Willheim, J. Wojta, K. Huber (Vienna, AT) Thursday, February 13, 2014 Thursday, 64 Poster Sessions – Thursday, February 13, 2014

P12 ADAMTS13, vWF I

Chair: J.A. Kremer-Hovinga (Berne, CH)

P12-1 An Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy and Safety of Voncento® in Subjects with Von Willebrand Disease. T. Lissitchkov1, E. Buevich2, K. Kuliczkowski3, O. Stasyshyn4, M. Fernandes De Oliveira5, A. Klukowska6, C. Joch7, W. Seifert7 (1Sofia, BG; 2Bernaul, RU; 3Wroclaw, PL; 4Lviv, UA; 5Rio De Janeiro, BR; 6Warsaw, PL; 7Marburg, DE)

P12-2 Co-occurrence of Von Willebrand Factor Modifiers in Subjects with and without von Willebrand Disease C. Von Depka, C. Detering, H. Martensen, E. Von Depka, M. Ekhlasi-Hundrieser, M. Von Depka (Hannover, DE)

P12-3 Progress Report for the International Registry of Patients with Hereditary Thrombotic Thrombocytopenic Purpura (TTP) – Upshaw-Schulman Syndrome M. Mansouri Taleghani1, Y. Fujimura2, J.N. George3, I. Hrachovinova4, P. Knöbl5, P. Quist-Paulsen6, A.S. Von Krogh6, R. Schneppenheim7, B. Lämmle1, J.A. Kremer Hovinga1 (1Berne, CH; 2Kashihara, JP; 3Oklahoma, US; 4Prague, CZ; 5Vienna, AT; 6Sluppen, NO; 7Hamburg, DE)

P12-4 Determination of Factor FVIII Binding Capacity and Affinity of Recombinant von Willebrand Factor on Solid Surfaces and in Solution M. Palige, G. Schrenk, R. Hartmann, E. Panholzer, M. Billwein, G. Gerstenbauer, S. Knappe, F. Scheiflinger, P. Turecek, M. Dockal (Vienna, AT)

P12-5 Diagnosis of von Willebrand Disease Type 2B by Measuring VWF Binding to Recombinant GPIba Y. Yildiz, U. Budde, W. Hassenpflug, T. Obser, F. Oyen, S. Schneppenheim, R. Schneppenheim (Hamburg, DE)

P12-6 The course of von Willebrand Parameters in Patients with von Willebrand Disease During Pregnancy C. Delbrück, S. Müller, V. Makki, J. Wenk, S. Alesci, S. Krekeler, Z. Wolf, W. Miesbach (Frankfurt, DE)

P12-7 Functional Characterization of Novel Missense Variants Residing in von Willebrand Factor Propeptide H. Yadegari, V. Ivaskevicius, J. Driesen, J. Oldenburg (Bonn, DE)

P12-8 Three Family Members with Von Willebrand Disease Collagen Binding Defect (Type 2M), Increased Bleeding Symptoms and Novel Vwf Mutation L. Nakamura1, J. Schelling1, U. Geisen1, U. Budde2, R. Schneppenheim2, B. Zieger1 (1Freiburg, DE; 2Hamburg, DE) Thursday, February 13, 2014 Thursday, 65 Poster Sessions – Thursday, February 13, 2014

P12-9 Late Onset and Pregnancy-induced Congenital Thrombotic Thrombocytopenic Purpura (Ttp) T. Falter1, J.A. Kremer Hovinga2, B. Lämmle1, I. Scharrer1 (1Mainz, DE; 2Berne, CH)

P12-10 Factor VIII Deficiency is Associated with Increased von Willebrand Factor Plasma Levels but Does Not Impact on Platelet Function. K. Kiouptsi, S. Jäckel, M. Lillich, D. Manukyan, U. Walter, C. Reinhardt (Mainz, DE)

P13 ADAMTS13, vWF II

Chair: A.-M. Bloch Münster (Aalborg, DK)

P13-1 Polyanionic molecules bind to VWF and are able to modulate VWF-platelet interaction S. Grässle, V. Huck, S. Schneider (Mannheim, DE)

P13-2 Managing Clinical Events of VWD Patients with thromboembolic risk factors: Results from Studies with a VWF with low FVIII (WILLFACT) J. Goudemand1, F. Bridey2, A. Borel-Derlon2, C. Chatelanaz2, C. Henriet2 (1Lille, FR; 2Münster, DE)

P13-3 VWF-platelet interactions under shear flow conditions - state-function relation- ship of soluble and immobilised VWF V. Huck1, M. Fallah2, S. Grässle1, C. Mess3, R. Schneppenheim4, A. Reininger5, M. Schneider6, S. Schneider1 (1Mannheim, DE; 2Konstanz, DE; 3Münster, DE; 4Hamburg, DE; 5Vienna, AT; 6Boston, US)

P13-4 Investigation of the interaction between VWF propeptide and highly multimerized therapeutic rVWF and its influence on FVIII stabilization G. Schrenk, M. Billwein, P. Stangl, F. Scheiflinger, P. Turecek (Vienna, AT)

P13-5 Discrepancy in inhibitor assessment of two acquired TTP patients using a static and a flow-based assay R. Grillberger, B. Gruber, S. Skalicky, B. Plaimauer, P. Turecek, F. Scheiflinger, H. Rottensteiner (Vienna, AT)

P13-6 Effect of ABO Blood group on the Ristocetin induced platelet function in patients with von Willebrand`s disease M. Alrifai, K. Heidinger, R. Fischer, B. Kemkes-Matthes (Giessen, DE)

P13-7 The ADAMTS13 Content in Commercially Available VWF/FVIII Concentrates Correlates with their VWF Triplet Structure C. Kannicht, C. Fisseau, W. Hofmann, B. Solecka, B. Fuchs (Berlin, DE)

P13-8 Development of a new ELISA test for the detection of antibodies in patients with von Willebrand disease U. Budde, H. El-Abd Müller, F. Langer, T. Obser, S. Schneppenheim, R. Dittmer,

Thursday, February 13, 2014 Thursday, R. Schneppenheim (Hamburg, DE) 66 Poster Sessions – Thursday, February 13, 2014

P13-9 Thrombotic thrombocytopenic purpura (TTP) and pregnancy T. Falter, V. Schmitt, S. Herold, I. Scharrer (Mainz, DE)

P13-10 Von Willebrand disease and unintentional childlessness: results from a pilot study M. Steiner, H. Müller, B. Krammer-Steiner (Rostock, DE)

P14 ADAMTS13, vWF III, Bleeding Disorders

Chair: S. Halvorsen (Oslo, NO)

P14-1 Acquired VWF-Inhibitor Responsive to Immunoglobuline Treatment P. Lodemann1, T. Held1, U. Budde2, W. Ludwig1, D. Peetz1 (1Berlin, DE; 2Hamburg, DE)

P14-2 Thrombin Generation Assay (TGA) for the Characterization of an Acquired Factor V (FV) Inhibitor D. Schmidt1, F. Steinhagen2, C. Schnabel2, B. Spath2, K. Holstein2, W. Fiedler2, C. Bokemeyer2, T. Renné2, F. Langer2 (1Utrecht, NL; 2Hamburg, DE)

P14-3 Recombinant ADAMTS13 can Normalize VWF Cleaving Activity in Rats with an Adjusted Inhibitor Titer A. Schiviz, B. Plaimauer, S. Kaufmann, S. Skalicky, G. Hoebarth, M. Wolfsegger, E. Muchitsch, P. Turecek, F. Scheiflinger, H. Rottensteiner (Vienna, AT)

P14-4 Epitope Mapping Via Selection of Anti-FVIII Antibody-specific Peptide Ligands Mimicking Antibody Epitopes J. Kahle, A. Scherger, A. Naumann, A. Kabiri, K. Becker-Peters, D. Stichel, A. Orlowski, D. Schwabe, C. Königs (Frankfurt, DE)

P14-5 Effect of Recombinant and Plasma-derived von Willebrand Factor on the Procoagulant Activity of Factor VIII inThrombin Generation Assays S. Till, S. Knappe, F. Scheiflinger, M. Dockal (Vienna, AT)

P14-6 Evaluation of a Rapid ADAMTS-13 Activity Test Based on Detection of vWF Degradation Rates Using Immunoturbidometric vWF Activity Testing H. Rühl, J. Müller, S. Fischer, J. Oldenburg, B. Pötzsch (Bonn, DE)

P14-7 Screening for Redox Partners of Vitamin K Epoxide Reductase Complex, Subunit 1-like 1 (VKORC1L1) K. Liphardt, M. Watzka, K. Czogalla, J. Oldenburg (Bonn, DE)

P14-8 AHEAD: a Non-interventional Registry to Provide Long-term ADVATE Outcome Data on Joint Health, HRQoL, ABRs, and Individualized Treatment J. Oldenburg1, K. Kurnik2, A. Huth-Kühne3, R. Zimmermann3, R. Klamroth4, D. Tsakiris5, I. Abraham6, A. Löw-Baselli7, P. Pina8, A. Reininger7, G. Spotts9 (1Bonn, DE; 2Munich, DE; 3Heidelberg, DE; 4Berlin-Friedrichshain, DE; 5Basel, CH; 6Unterschleißheim, DE; 7Vienna, AT; 8 9

Glattpark, CH; Westlake Village, US) February 13, 2014 Thursday, 67 Poster Sessions – Thursday, February 13, 2014

P14-9 Continuing Surveillance of Tolerability and Treatment Efficacy in von Willebrand’s Disease – First Results of the New Wilate-STATE Study S. Alesci1, J. Feddern2, S. Halimeh3, J. Koscielny4, T. Lang5, M. Rieke5 (1Mannheim, DE; 2Langenfeld, DE; 3Duisburg, DE; 4Berlin, DE; 5Hohne, DE)

P14-10 Peripheral Arterio-venous Shunts for Venous Access in Children with Haemophilia K. Thom1, T. Hoelzenbein2, N. Jones2, K. Zwiauer3, G. Endres4, C. Male1 (1Vienna, AT; 2Salzburg, AT; 3St. Pölten, AT; 4Bregenz, AT) Thursday, February 13, 2014 Thursday, 68 Poster Sessions – Friday, February 14, 2014

Poster Sessions 15–28 14:30 – 15:45 Poster authors of Poster Sessions 15-28 are kindly asked to mount their posters after the removal time of Poster Sessions 1-14, however latest on Friday (February 14, 2014) between 08:00–10:00. Posters need to be removed on Friday (February 14, 2014) between 19:00–19:30.

P15 Bleeding Disorders I

Chair: C. Mannhalter (Vienna, AT)

P15-1 Tailored Prophylaxis and Telemedicine, an Ideal Couple to Improve Outcome in Hemophilia Therapy B. Siegmund, H. Pollmann (Münster, DE)

P15-2 EpiNine – Update of a Non-interventional, Multicentre Study in Patients with Haemophilia B C. Königs1, R. Klamroth2, C. Wermes3, V. Wiegering4, S. Halimeh5, R. Fischer6, M. Krause7, P. Sommerer8, C. Bidlingmaier9 (1Frankfurt, DE; 2Berlin, DE; 3Hannover, DE; 4Würzburg, DE; 5Duisburg, DE; 6Gießen, DE; 7Wiesbaden, DE; 8Marburg, DE; 9Munich, DE)

P15-3 Female Patient with Severe Hemophilia A and 1p36 Deletion Syndrome M. Gothwal1, A. Pavlova2, L. Nakamura1, I. Hainmann1, A. Gencik3, S. Rost4, J. Oldenburg2, B. Zieger1 (1Freiburg, DE; 2Bonn, DE; 3Osnabrück, DE; 4Würzburg, DE)

P15-4 Late-onset Systemic Lupus Erythematosus (SLE) with Concomitant Acquired Hemophilia A (AHA) and Acquired von Willebrand Syndrome (AVWS) C. Dicke, K. Holstein, R. Dittmer, S. Schneppenheim, C. Bokemeyer, C. Iking-Konert, U. Budde, F. Langer (Hamburg, DE)

P15-5 Combined Factor VII and Factor X Deficiency: Different Mechanisms of Inheritance A. Pavlova1, J. Driesen1, P. De Moerloose2, U. Harbrecht1, J. Oldenburg1 (1Bonn, DE; 2Geneva, CH)

P15-6 Unbalanced X-chromosome Inactivation Combined with a Del22-type1 Inversion Results in Severe Haemophilia A in a Female B. Pezeshkpoor, A. Pavlova, J. Oldenburg (Bonn, DE)

P15-7 Findings of the HomeMHA Project – Implementation of a Mobile Haemophilia Outpatient’s Care in Germany S. Von Mackensen1, C. Schleicher2, K. Freidinger2, S. Heine2, N. Graf2, H. Eichler2 (1Hamburg, DE, 2Homburg, DE)

P15-8 Latest Results From The PUP-GCP Clinical Trial: A Low Inhibitor Rate in Previously Untreated Patients with Severe Hemophilia a Treated With Octanate A. Klukowska1, M. Jansen2, V. Komrska3, P. Laguna1, V. Vdovin4, S. Knaub5 (1Warsaw, PL; 2Vienna, AT; 3Prague, CZ; 4Moscow, RU; 5Lachen SZ, CH) Friday, February 14, 2014 Friday, 69 Poster Sessions – Friday, February 14, 2014

P15-9 Evaluation of Bleeding Severity in Children with Hereditary Thrombocytopathies: Results of the THROMKID Study. R. Knöfler1, M. Olivieri2, J. Lohse1, S. Weickardt1, U. Range1, W. Streif3 (1Dresden, DE; 2Munich, DE; 3Innsbruck, AT)

P15-10 Delayed Diagnosis of Severe Acquired Haemphilia in a Post-surgical ICU Patient after Treatment with New Oral Anticoagulants F. Prüller, F. Bauer, R. Raggam, P. Kohek, M. Zotter, A. Münch, J. Horina, A. Wölfler, B. Huber-Krassnitzer, A. Preininger (Graz, AT)

P16 Bleeding Disorders II

Chair: R.G. Kiss (Budapest HU)

P16-1 Beriate® P in the treatment of patients with haemophilia A: Update of a Long-term Pharmacovigilance R. Klamroth1, S. Holzhauer2, C. Heller3, P. Sommerer4, K. Kurnik For The Beriate® P Pharmacovigilance Group5 (1Berlin-Friedrichshain, DE; 2Berlin, DE; 3Frankfurt, DE; 4Marburg, DE; 5Munich, DE)

P16-2 Pharmacokinetics, Efficacy and Safety of a Recombinant Factor IX in Previously Treated Patients with Severe or Moderately Severe Hemophilia B J. Windyga1, T. Lissitchkov2, O. Stasyshyn3, V. Mamonov4, L. Rusen5, M. Oh6, M. Chapman7, B. Pavlova7, W. Wong6, B. Abbuehl7 (1Warsaw, PL; 2Sofia, BG; 3Lviv, UA; 4Moscow, RU; 5Bucharest, RO; 6Westlake Village, US; 7Vienna, AT)

P16-3 Functional Investigation of Three GGCX Splice-Site Mutations M. Watzka, J. Sóos, K. Czogalla, K. Liphardt, J. Oldenburg (Bonn, DE)

P16-4 Dosing of Recombinant Factor VIII Fc Fusion Protein: Analysis from the A-LONG Study J. Oldenburg1, A. Shapiro2, M. Ragni3, R. Kulkarni4, S. Kulke5, J. Potts5, S. Neelakantan5, I. Nestorov5, J. Dumont5, H. Jiang5, A. Brennan5, G. Pierce5 (1Bonn, DE; 2Indianapolis, US; 3Pittsburgh, US; 4East Lansing, US; 5Cambridge, US)

P16-5 Association Between Bleeding and Predicted FVIII Activity in Patients with Severe Haemophilia A Treated with Recombinant Factor VIII Fc Fusion Protein R. Klamroth1, J. Pasi2, J. Potts3, S. Li3, P. Wang3, S. Kulke3, G. Pierce3, H. Jiang3 (1Berlin, DE; 2London, UK; 3Cambridge, US)

P16-6 Haemoassist® 2 – New functionalities and European roll-out of the Therapy Management System for Haemophilia M. Schulz1, R. Klamroth1, C. Wermes2, J. Dalsgaard Nielsen3, J. Grimm4, M. Westfeld1 (1Berlin, DE; 2Hannover, DE; 3Copenhagen, DK; 4Magdeburg, DE) Friday, February 14, 2014 Friday, 70 Poster Sessions – Friday, February 14, 2014

P16-7 Perioperative Haemostatic Management with a Recombinant Factor IX in Previously Treated Patients with Severe or Moderately Severe Hemophilia B J. Windyga1, T. Lissitchkov2, O. Stasyshyn3, V. Mamonov4, H. Ghandehari5, M. Chapman6, S. Fritsch6, B. Pavlova6, W. Wong5, B. Abbuehl6 (1Warsaw, PL; 2Sofia, BG; 3Lviv, UA; 4Moscow, RU; 5Westlake Village, US; 6Vienna, AT)

P16-8 Inhibitor Development and Management in Three Non-severe Haemophilia A Patients with T295A Variant V. Ivaskevicius, G. Goldmann, N. Marquardt, C. Klein, S. Horneff, J. Oldenburg (Bonn, DE)

P16-9 Health-Related Quality of Life and Transitional Life Events in Adolescents and Young Adults With Haemophilia A S. Von Mackensen1, S. Riva2, R. Klamroth3 (1Hamburg, DE; 2Lugano, CH; 3Berlin, DE)

P16-10 Efficacy, Immunogenicity, Pharmacokinetics, and Safety of Human-cl rhFVIII – a GCP Study in Children with Severe Haemophilia A R. Liesner1, M. Jansen2, A. Klukowska3, V. Vdovin4, T. Szczepa ski5, S. Knaub6 (1London, UK; 2Vienna, AT; 3Warsaw, PL; 4Moscow, RU; 5Zabrze, PL; 6Lachen SZ, CH)

P17 Bleeding Disorders III

Chair: J. Siller-Matula (Vienna, AT)

P17-1 Routine Treatment of Patients with Haemophilia A with KOGENATE® Bayer - the EffeKt-Study R. Klamroth1, W. Miesbach2, P. Staritz3, K. Achilles4 (1Berlin-Friedrichshain, DE; 2Frankfurt, DE; 3Heidelberg, DE; 4Leverkusen, DE)

P17-2 Vitamin K epoxide reductase (VKOR) Co-expression is not Required to Yield Fully Active Recombinant Vitamin K-dependent (VKD) Blood Coagulation Factors E. Böhm, F. Horling, S. Knappe, J. Koehn, J. Lengler, S. Till, F. Scheiflinger, M. Dockal (Vienna, AT)

P17-3 Smart-medication Allows a Rapid and Comprehensive Overview of Haemophilia Home Treatment W. Mondorf1, A. Roesch1, D. Schmoldt1, H. Pollmann2 (1Frankfurt, DE; 2Münster, DE)

P17-4 Recombinant or Plasma Derived Factor Concentrates – Results of a Self Evaluation in Patients with Haemophilia in Germany W. Mondorf1, W. Kalnins2, R. Klamroth3 (1Frankfurt, DE; 2Nettersheim-Marmagen, DE; 3Berlin, DE)

P17-5 The Effect of a Potent Tissue Factor Pathway Inhibitor (TFPI) Inhibitory Fusion Peptide on TFPI Clearance R. Hartmann, C. Redl, E. Panholzer, A. Kolm, W. Hoellriegl, F. Scheiflinger, M. Dockal (Vienna, AT) Friday, February 14, 2014 Friday, 71 Poster Sessions – Friday, February 14, 2014

P17-6 Plasma-derived Factor IX Concentrates, but not rFIX, Bind to Non-activated Platelets, Activate Platelets and Induce Platelet Microparticle Formation A. Bertling, K. Grieß, M. Brodde, A. Müller, B. Kehrel (Münster, DE)

P17-7 Recombinant FVIII-FS for the Treatment of Haemophilia A: Update of a Long-term Pharmacovigilance Project. J. Oldenburg1, P. Petrini2, A. Faradji3, I. Pabinger4, M. Jürs5, P. Staritz6 (1Bonn, DE; 2Stockholm, SE; 3Strasbourg, FR; 4Vienna, AT; 5Marburg, DE; 6Heidelberg, DE)

P17-8 Development of the Disease-Specific Burden Scale for Caregivers of Haemophilia Children–the HEMOphilia associated Caregiver Burden Scale (HEMOCABTM) S. Von Mackensen1, T. Wisniewski2, L. Valentino3 (1Hamburg, DE; 2Princeton, US; 3Chicago, US)

P17-9 The Role of Fibrinolysis Stimulation and Bleeding Tendency in Patients with Systemic Mast Cell Activation Disorder M. Vysniauskaite1, G. Molderings1, I. Haussels1, S. Ohlenforst1, H. Rühl1, A. Selbitz1, S. Unkrig1, P. Dreßen2, J. Homann1, S. Brettner3, H. Seidel4, J. Oldenburg1, H. Hertfelder1 (1Bonn, DE; 2Eitorf, DE; 3Waldbröl, DE; 4Düsseldorf, DE)

P17-10 EQA in Thrombelastography A. Dick1, M. Kutsch1, D. Illigen2, M. Spannagl1 (1Munich, DE; 2Düsseldorf, DE)

P18 Bleeding Disorders IV

Chair: E. Mahla (Graz, AT)

P18-1 Affinity Assessment of FVIII-specific Antibodies in Hemophilia Patients – Comparison of a Competitive Immunoassay with Alternative Technologies C. Hofbauer1, P. Allacher1, F. Horling1, J. Lawo1, J. Oldenburg2, A. Tiede3, C. Male1, J. Windyga4, P. Knöbl1, G. Schrenk1, J. Koehn1, F. Scheiflinger1, B. Reipert1 (1Vienna, AT; 2Bonn, DE; 3Hannover, DE; 4Warsaw, PL)

P18-2 Successful Second ITI with Factor IX and Combined Immunosuppressive Therapy in a Patient with Severe Hemophilia B and Recurrent Factor IX-Inhibitor K. Holstein, R. Schneppenheim, J. Schrum, C. Bokemeyer, F. Langer (Hamburg, DE)

P18-3 Association Between Predicted FVIII Levels and Risk of Bleeding in Clinical Trials with Turoctocog Alfa, a New rFVIII Product from Novo Nordisk R. Klamroth1, M. Ozelo2, D. Veljkovic3, M. Misgav4, R. Nielsen5, A. Groth5 (1Berlin-Friedrichshain, DE; 2Sao Paulo, BR; 3Belgrade, RS; 4Tel Aviv, IL; 5Søborg, DK)

P18-4 Impact of Social Status and Disease Influence on Outcome Parameters of Adult Patients with Haemophilia (PWH): An Explorative Single-Centre Pilot Study K. Holstein, S. Von Mackensen, J. Gäßler, B. Lentz, C. Bokemeyer, F. Langer (Hamburg, DE) Friday, February 14, 2014 Friday, 72 Poster Sessions – Friday, February 14, 2014

P18-5 Factor VIII Assessment Using One-stage Clot and Chromogenic Assay in Trials Investigating Pharmacokinetics of Different FVIII Products A. Tiede1, M. Ezban2, T. Krogh-Meibom3, T. Saugstrup4, S. Bassus5 (1Hannover, DE; 2Måløv, DK; 3Tjele, DK; 4Søborg, DK; 5Mainz, DE)

P18-6 Acquired von Willebrand Disease Type 2 in Two Children After Bone Marrow Transplantation I. Wieland, C. Bettoni, B. Maecker-Kolhoff, R. Beier, C. Kratz, K. Sykora (Hannover, DE)

P18-7 Validation and Psychometric Testing of the English HEP-Test-Q for the Assessment of Subjective Physical Performance in Haemophilia Patients S. Von Mackensen1, D. Czepa2, K. Khair3, L. Valentino4, T. Hilberg2 (1Hamburg, DE; 2Wuppertal, DE; 3London, UK; 4Chicago, US)

P18-8 Consumption of FVIII Concentrate For On-Demand and Prophylactic Treatment with Human-cl rhFVIII in Adult Patients with Severe Haemophilia A. Tiede1, J. Bichler2, S. Knaub2, J. Oldenburg3 (1Hanover, DE; 2Lachen SZ, CH; 3Bonn, DE)

P18-9 The Influence of the Factor 8 D1241E Gene Polymorphism on FVIII Activity in Patients with Mild Hemophilia A B. Horvath, S. Kepa, R. Sunder-Plassmann, C. Ay, P. Quehenberger, I. Pabinger, C. Mannhalter (Vienna, AT)

P19 Bleeding Disorders V

Chair: A. D’Angelo (Milan, IT)

P19-1 An Adapted Pain Questionnaire as a Qualified Routine Tool for Patients with Haemophilia K. Holstein1, C. Königs2, R. Mahnel2, M. Krause3 (1Hamburg, DE; 2Frankfurt, DE; 3Wiesbaden, DE)

P19-2 Severe Factor XII Deficiency and Pregnancy – a Case Report J. Gross, B. Hummel, J. Schenk, H. Eichler (Homburg, DE)

P19-3 Influence of Co-morbidities on Annualised Bleeding Rates in Patients with Severe Haemophilia A: Experiences from a Turoctocog Alfa Prophylaxis Trial R. Klamroth1, T. Andreeva2, T. Suzuki3, R. Nielsen4, E. Andersen4, A. Lindblom4 (1Berlin-Friedrichshain, DE; 2St. Petersburg, RU; 3Tokyo, JP; 4Søborg, DK)

P19-4 Ultrasonography of Joints and Correlation with Function in Haemophilic Arthropathy – Interim Results of a Clinical Pilot Trial M. Sigl-Kraetzig1, M. Wendel2, A. Seuser2 (1Blaubeuren, DE; 2Bonn, DE)

P19-5 Overview of a Global Clinical Trial Programme with Turoctocog Alfa, a New Recombinant Factor VIII: the Guardian™ Programme A. Tiede1, P. Laguna2, V. Vdovin3, L. Rageliene4, L. Abad Franch5, S. Bassus6 (1Hanover, DE; 2 3 4 5 6

Warsaw, PL; Moscow, RU; Vilnius, LT; Zürich, CH; Mainz, DE) February 14, 2014 Friday, 73 Poster Sessions – Friday, February 14, 2014

P19-6 Adherence to Haemophilia Treatment – How to Assess it? S. Von Mackensen (Hamburg, DE)

P19-7 A Very Rare Case of Bleeding Tendency in Germany J. Ringwald, C. Scheuerer, J. Strobel, R. Eckstein (Erlangen, DE)

P19-8 A Clinical Study In Previously Untreated Patients with Severe Haemophilia A – Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

R. Liesner1, M. Jansen2, S. Knaub3 (1London, UK; 2Vienna, AT; 3Lachen SZ, CH)

P19-9 Results of Ankle Prosthesis in Patients with Severe Haemophilic Arthropathy – Follow Up M. Krause1, M. Preis1, C. Kirchmaier1, C. Königs2, G. Von Salis-Soglio3, R. Scholz3, U. Scholz3 (1Wiesbaden, DE; 2Frankfurt, DE; 3Leipzig, DE)

P20 FXIII, Fibrinogen I

Chair: M. Geiger (Vienna, AT)

P20-1 Novel Mutations in the Fibrinogen Genes Causing Various Coagulation Disorders M. Ekhlasi-Hundrieser, C. Halves, C. Detering, M. Von Depka (Hannover, DE)

P20-2 FcgammaR2B Blockade Prevents FVIII-specific Recall Response and is Associated with Distinctive Alterations in the FVIII-specific Cytokine Profile. N. Vollack, A. Trummer, A. Tiede, S. Werwitzke (Hannover, DE)

P20-3 Perioperative Management in a Case of Hereditary Hypodysfibrinogenemia – Fibrinogen Philadelphia with Bleeding and Thrombosis K. Schilling, M. Hofmann, Y. Walter, M. Ramsthaler, K. Reinhart, A. Hochhaus (Jena, DE)

P20-4 Fast and Reliable Estimation of “Plasma-equivalent” Fibrinogen Levels by Measurement of Whole Blood Fibrinogen Using a Steel Ball Coagulometer. C. Schlimp, A. Khadem, A. Klotz, C. Solomon, H. Redl, H. Schöchl (Vienna, AT)

P20-5 The Effect of Factor XIII and Other Regulators of Fibrinolysis on the Outcome of Thrombolysis in Ischemic Stroke Patients Z. Bagoly, E.G. Székely, K.R. Kovács, Z.A. Mezei, A. Orosz, É. Katona, J. Kappelmayer, L. Csiba, L. Muszbek (Debrecen, HU)

P20-6 Oxidative Modification of Fibrinogen and Plasma Fibrin-stabilizing Factor M. Rosenfeld, A. Bychkova, A. Shchegolikhin, V. Leonova, M. Biryukova, E. Kostanova (Moscow, RU) Friday, February 14, 2014 Friday, 74 Poster Sessions – Friday, February 14, 2014

P20-7 In Silico Analysis of Eight Novel F13A1 Gene Missense Mutations in Patients with Mild FXIII Deficiency V. Ivaskevicius1, A. Biswas1, A. Thomas1, M. Varvenne2, B. Brand3, H. Rott4, I. Haussels1, H. Rühl1, U. Scholz5, R. Klamroth6, J. Oldenburg1 (1Bonn, DE; 2Hannover, DE; 3Zürich, CH; 4Duisburg, DE; 5Leipzig, DE; 6Berlin-Friedrichshain, DE)

P20-8 Co-localization Analysis of Pathological FXIIIB Subunit Cysteine Variants Supports an Indirect Effect on Secretion. A. Thomas, A. Biswas, V. Ivaskevicius, S. Lyonga, J. Oldenburg (Bonn, DE)

P20-9 UV-C Treatment to Inactivate Viruses in Intermediates of Biologicals without Denaturing Desired Protein C. Dreier, A. Gröner (Marburg, DE)

P20-10 Factor VII Activating Protease (FSAP) Regulates Fibrinolysis Independent of Pro-uPA/ Pro-tPA Activation, but by Modifying Fibrin Clot Structure M. Etscheid1, J. Lankes1, A. Undas2, M. Zabczyk2, O. Rannou3, S. Kanse4 (1Langen, DE; 2Krakow, PL; 3Giessen, DE; 4Oslo, NO)

P21 Fibrinogen II, Thrombin, Thrombocytopaenia

Chair: H. Redl (Vienna, AT)

P21-1 Ex-vivo Prothrombin Complex Concentrates Are Effective in Reversing Dabigatran-induced Coagulopathy in Pigs O. Grottke1, J. Van Ryn2, H. Spronk3, R. Rossaint1 (1Aachen, DE; 2Biberach, DE; 3Maastricht, NL)

P21-2 Health-Related Quality of Life in Children with Immune Thrombocytopenia: Cross-Cultural Validation and Psychometric Testing of the ITP-QoL S. Von Mackensen1, G. Lassandro2, R. Ljung3, U. Tedgard3, P. Giordano2 (1Hamburg, DE; 2Bari, IT; 3Malmoe, SE)

P21-3 Micropatterned Array to Assess the Interaction of Single Platelets with Platelet Factor 4-Heparin-IgG Complexes N. Medvedev, R. Palankar, K. Krauel, A. Greinacher, M. Delcea (Greifswald, DE)

P21-4 Quantification of Thrombin-Antithrombin Complexes (TAT) in Human Citrated Plasma Based on LOCI Technology S. Stephan, M. Ehm, G. Christ, C. Duwe, H. Althaus, B. Fischer, M. Hahn, H. Schwarz, N. Zander (Marburg, DE)

P21-5 The Use of Desulfated Heparin to Prevent Platelet Activation by Antiprotamin/ Heparin Antibodies T. Bakchoul, R. Jouni, H. Zöllner, S. Brandt, J. Bagemühl, M. Delcea, A. Greinacher (Greifswald, DE) Friday, February 14, 2014 Friday, 75 Poster Sessions – Friday, February 14, 2014

P21-6 Clinical Experience with the Zymutest HIA IgG (Hyphen Biomed) in a Routine Laboratory Setting – HIT or PIT? F. Bergmann, A. Czwalinna, B. Steggewentz, A. Siegel, B. Arndt, A. Gröning (Hannover, DE)

P21-7 Epidemiology and Therapy of Patients with Adult Immune Thrombocytopenia: a single-center retrospective analysis C. Feistritzer, M. Henkel, W. Weyrer, S. Wildner, G. Gastl, M. Steurer (Innsbruck, AT)

P21-8 Global Development Plan for a Double Virus Inactivated Fibrinogen Concentrate for the Treatment of Congenital Fibrinogen Deficiency B. Schwartz1, S. Knaub2, F. Peyvandi3 (1Hoboken, US; 2Lachen SZ, CH; 3Milan, IT)

P21-9 Succesful Treatment with Coumadin in a Patient with Afribrinogenemia S. Alesci, C. Dempfle (Mannheim, DE)

P21-10 Rational of Fibrinogen Replacement in Disturbances of Fibrin Polymerization – Clues drawn from a Study in Cardiopulmonary Bypass Surgery (CPB) J. Wieding1, O. Rode2, F. Flachsbart1, D. Zenker1 (1Göttingen, DE; 2Fulda, DE)

P22 Platelet Aspects II

Chair: C. Kopp (Vienna, AT)

P22-1 The Automated Morphometry of Single Platelets Allows for the Differentiation of Platelets Activated with ADP or TRAP M. Kraus1, H. Neeb2, E.F. Strasser3 (1Grünwald, DE; 2Remagen, DE; 3Erlangen, DE)

P22-2 Contribution of Cytoskeleton Forces and Shear to the Unfolding of Fibronectin H. Nguyen, K. Huynh, R. Scharf, V. Stoldt (Düsseldorf, DE)

P22-3 Impact of Leu33/Pro33 Polymorphism on Human Platelet Integrin IIb 3 – Ligand Interaction Under Abnormally High Shear Conditions V. Stoldt, M. Gyenes, R. Scharf (Düsseldorf, DE)

P22-4 Automated Morphometry of Single Platelets Allows for the Monitoring and Quantification of the Entire Platelet Shape Change Process M. Kraus1, E.F. Strasser2, H. Neeb3 (1Grünwald, DE; 2Erlangen, DE; 3Remagen, DE)

P22-5 Retinoic Acid Receptor Alpha Guides Platelet Actin Cytoskeletal Dynamics H. Schwertz1, M. Rondina2, A. Weyrich2 (1Greifswald, DE; 2Salt Lake City, US)

P22-6 Human Platelets Affect Plasma Complement C3 Activation by Escherichia Coli I. Arbesu, M. Fischer, C. Mannhalter (Vienna, AT) Friday, February 14, 2014 Friday, 76 Poster Sessions – Friday, February 14, 2014

P22-7 Feedback-activation of Platelet Thrombin Generation In Vitro Reveals Platelet Hypercoagulability in Patients with Stable Coronary Artery Disease K. Rosenplänter, M. Döhrmann, K. Schwierczek, U. Walter, T. Gori, B. Schnorbus, K. Jurk (Mainz, DE)

P22-8 Basic Mechanisms of Platelet Thrombin Amplification: Critical Role of CD36 M. Döhrmann, K. Schwierczek, U. Walter, K. Jurk (Mainz, DE)

P22-9 TLR2 Promotes Arterial Thrombus Formation Via von Willebrand Factor Under Non-infectious Conditions S. Jäckel1, K. Kiouptsi1, N. Hörmann1, C. Reiss1, K. Alber1, M.-L. Von Brühl2, S. Massberg2, W. Ruf1, U. Walter1, C. Reinhardt1 (1Mainz, DE; 2Munich, DE)

P23 Platelet Aspects III

Chair: S. Eichinger-Hasenauer (Vienna, AT)

P23-1 Assessment of the Response to Aspirin in Patients with Myeloproliferative Neoplasms: a Comparison of the PFA-100 with Multiple Electrode Aggregometry C. Robier, M. Neubauer, F. Quehenberger, M. Stettin, P. Neumeister (Graz, AT)

P23-2 Characterization of Fibronectin Assembly by Adherent Platelets Under Flow Conditions: Effect of Shear Stress and Role of 3 Integrins K. Huynh, V. Stoldt, R. Scharf (Düsseldorf, DE)

P23-3 Flow Cytometric Detection of Varying Binding of Activated Recombinant Factor VII to Human Platelets and of a High rFVIIa Binding Subpopulation J. Koehn, E. Böhm, A. Sedivy, M. Dockal, F. Scheiflinger (Vienna, AT)

P23-4 Simple Geometric Measures of Platelet Shape Allow for Aa Accurate Prediction Oa The Number of Pseudopods per Platelet H. Neeb1, E.F. Strasser2, M. Kraus3 (1Remagen, DE; 2Erlangen, DE; 3Grünwald, DE)

P23-5 Platelet gene polymorphisms in relation to the risk group of patients with acute myocardial infarction J. Ulehlova, L. Slavik, V. Krcova, J. Vaclavik, J. Kucerova (Olomouc, CZ)

P23-6 Regulation of prothrombinase complex by platelet poly-P B. Arneth, T. Chavakis, G. Siegert (Dresden, DE)

P23-7 Antiplatelet properties of the NO independent sGC stimulator Riociguat (Bay 63-2561) C. Reiß1, V. Bischoff1, S. Gambaryan2, I. Mindukshev3, A. Friebe2, U. Walter1 (1Mainz, DE; 2Würzburg, DE; 3St. Petersburg, RU) Friday, February 14, 2014 Friday, 77 Poster Sessions – Friday, February 14, 2014

P23-8 Anti-thrombotic and anti-inflammatory properties of AChE-Inhibitor treatment in Alzheimer disease patients A. Schedel, L. Hausner, A. Sarin, D. Hassmann, L. Froelich, P. Bugert (Mannheim, DE)

P23-9 Case report: Revelation of an acquired Thrombocytopathy in an old multimorbid Patient P. Würtinger, L. Loacker, D. Fries, A. Griesmacher, G. Weigel (Innsbruck, AT)

P24 Antiplatelet Agents, Pharmacogenetics

Chair: M. Brodmann (Graz, AT)

P24-1 Sex differences in self-managed oral anticoagulant therapy: 6,900 patient-years of follow-up. H. Nilsson1, E. Grove1, T. Larsen2, P. Nielsen2, F. Skjøth2, M. Maegaard1, T. Christensen1 (1Aarhus, DK; 2Aalborg, DK)

P24-2 Influence of Different Blood Preparations on TPO Clearance F. Wenzel1, M. Hauser2, J. Rox2, J. Fischer2, G. Giers2 (1Villingen-Schwenningen, DE; 2Düsseldorf, DE)

P24-3 Single Molecule Interaction between Platelet factor 4 (PF4) and Heparin of Different Lengths T.H. Nguyen, M. Kreimann, S. Brandt, K. Krauel, A. Greinacher, M. Delcea (Greifswald, DE)

P24-4 Plasma derived factor VIII products induce in vitro osteoblast apoptosis M. Brodde, A. Müller, B. Kehrel (Münster, DE)

P24-5 Hemorrhagic risk stratification of medical in-patients taking antithrombotic drugs: A case control study V. Rancitelli, E. Allemand, A.C. Frigo, M.L. Randi, F. Fabris (Padova, IT)

P24-6 Does the Inhibition of P2Y12 Inhibit the Production of Thromboxane A2 by Platelets? M. Scavone, E. Femia, K. Germanovich, V. Caroppo, M. Cattaneo (Milan, IT)

P24-7 Anticoagulant Therapy in the Conditions of Anticoagulant Clinic N. Vorobyeva, A. Rogozina (Arkhangelsk, RU)

P24-8 Glycosylation Analysis of a New Recombinant Factor IX (RIXUBIS) – Reveals Novel Structural Features B. Seyfried1, A. Foettinger-Vacha2, M. Kaliwoda2, A. Mitterer2 (1Orth, AT; 2Vienna, AT)

P24-9 Optimized Treatment of High-risk Pregnancies H. Kiesewetter, H., F.-P. Schmidt, R. Becker (Berlin, DE) Friday, February 14, 2014 Friday, 78 Poster Sessions – Friday, February 14, 2014

P25 Procoagulants

Chair: T. Backchoul (Greifswald, DE)

P25-1 Reversal of the Effects of New Oral Anticoagulants by Treatment with FEIBA A. Schiviz, G. Schrenk, B. Dietrich, P. Turecek, F. Scheiflinger, E. Muchitsch, W. Hoellriegl (Vienna, AT)

P25-2 A Cyclic Inhibiotry Peptide Co-crystalized with Kunitz Domain 1 and 2 of Tissue Factor Pathway Inhibitor (TFPI) M. Dockal1, R. Hartmann1, M. Fries1, K. Prohaska1, R. Pachlinger1, T. Polakowski2, J. Brandstetter3, F. Scheiflinger1 (1Vienna, AT; 2Berlin, DE; 3Salzburg, AT)

P25-3 Neutralization of Hemorrhage Induced by Direct Factor Xa and Thrombin Inhibitors by Prothrombin Complex Concentrates in a Rat Model W. Jeske, V. Escalante, B. Mcguire, J. Walenga, J. Fareed, M. Bakhos (Maywood, US)

P25-4 Distribution of Cogulation Therapy During Liver Transplantation K. Johanning, H. Eismann, A. Gerdes, S. Hoeft, L. Friedrich, C. Schumacher (Hannover, DE)

P25-5 Oral Anti-Factor Xa and Factor IIa Agent Mediated Inhibition of Tissue-Factor Mediated Generation of Thrombin in Prothrombin Complex Concentrates D. Syed1, D. Hoppensteadt1, D. Kahn1, J. Harenberg2, J. Fareed1 (1Maywood, US; 2Mannheim, DE)

P25-6 Reversal of Oral Anticoagulation by PCC, aPCC and Rfviia In Vitro A. Pilgrimm-Thorp, D. Pillitteri, T. Scholz, M. Krause, C. Kirchmaier (Wiesbaden, DE)

P25-7 A Comparison of Efficacy Between Recombinant Aactivated Factor VII (Aryo- Seven TM) and NovoSeven® in Patients with Congenital Factor VII Deficiency M. Faranoush1, H. Abolghasemi1, F. Mahboudi1, G. Toogeh1, M. Karimi2, P. Eshghi1, M. Managhchi1, H. Hoorfar3, B. Keikhaei Dehdezi4, A. Mehrvar1, B. Khoeiny5, B. Vaziri1, K. Kamyar5, R. Heshmat1, M.R. Baghaeipour1, N.B. Mirbehbahani6, R. Fayazfar7, M. Ahmadinejad1, R. Eshraghi8, M. Naderi4 (1Tehran, IR; 2Shiraz, IR; 3Isfahan, IR; 4Ahwaz, IR; 5Karaj, IR; 6Gorgan, IR; 7Kerman, IR; 8Maywood, US)

P25-8 Compositional Differences in Commercially Available Recombinant Factor VIIa Preparations and their Activity in a Prothrombin System D. Kahn, N. Sadeghi, D. Hoppensteadt, J. Fareed (Maywood, US)

P25-9 Pattern and Management of Bleeding Complications with New Oral Anticoagulants – Results of the Prospective Dresden NOAC Registry (NCT01588119) K. Förster, F. Ebertz, V. Gelbricht, C. Köhler, S. Werth, L. Tittl, J. Beyer-Westendorf (Dresden, DE)

P25-10 Reversal of Dabigatran Inhibition on Coagulation In Vitro T. Lindahl1, M. Wallstedt1, K. Gustafsson1, A. Hillarp2 (1Linköping, SE; 2Malmö, SE) Friday, February 14, 2014 Friday, 79 Poster Sessions – Friday, February 14, 2014

P26 Coagulation

Chair: K. Schrör (Düsseldorf, DE)

P26-1 Selection and Characterization of Single-chain Variable Antibody Fragments (scFvs) Specific for Anti-FVIII Antibodies K. Brettschneider, A. Naumann, J. Kahle, S. Neimanis, D. Schwabe, C. Heller, T. Klingebiel, C. Königs (Frankfurt, DE)

P26-2 Simulation of Massive Transfusion and the RCC to FFP Ratio T. Schulzki (Chur, CH)

P26-3 Absolute and Relative Coagulation Factor Content in Three Prothrombin Complex Concentrates Licensed in Switzerland – Time to Rethink Normalization? L. Asmis1, I. Bressa1, S. Hunziker1, T. Brinkmann2 (1Zürich, CH; 2Geneva, CH)

P26-4 Effects of Combined Administration of FEIBA and Recombinant FVIIa in Hemophilia A Mice W. Hoellriegl, A. Schiviz, C. Piskernik, P. Leidenmuehler, A. Bauer, S. Knappe, M. Dockal, F. Scheiflinger, B. Dietrich, E. Muchitsch (Vienna, AT)

P26-5 A Generic Version of Recombinant Factor VIIa is Comparable to the Branded Product (NovoSeven) J. Fareed, D. Kahn, N. Sadeghi, W. Jeske, D. Hoppensteadt (Maywood, US)

P26-6 Diabetic Therapy is Potentially Responsible for Preimmunization Against Protamineheparin Complexes in Diabetic Patients Undergoing Cardiac Surgery H. Zöllner1, R. Jouni1, J. Amiral2, J. Bagemühl1, U. Strobel1, A. Greinacher1, T. Bakchoul1 (1Greifswald, DE; 2Neuville Sur Oise, FR)

P26-7 Resuscitation with Different Volume Expanders does not Influence Coagulation After Antidoting Dabigatran in a Pig Model of Hemorrhagic Shock H. Spronk1, J. Van Ryn2, C. Zentai3, H. Ten Cate1, R. Rossaint3, O. Grottke3 (1Maastricht, NL; 2Biberach, DE; 3Aachen, DE)

P26-8 Resuscitation with Different Infusion Solutions does not Influence Binding of Dabigatran to its Specific Antidote in a Pig Model of Hemorrhagic Shock O. Grottke1, J. Van Ryn2, C. Zentai1, H. Ten Cate3, R. Rossaint1, H. Spronk3 (1Aachen, DE; 2Biberach, DE; 3Maastricht, NL)

P26-9 A Comparison of Efficacy Between Recombinant Activated Factor VII (AryoSevenTM) and NovoSeven® in Patients with Congential Factor VII Deficiency M. Faranoush1, H. Abolghasemi1, G. Toogeh1, M. Karimi2, P. Eshghi1, M. Managhchi1, H. Hoorfar3, B. Keikhaei Dehdezi4, A. Mehrvar1, B. Khoeiny5, K. Kamyar5, R. Heshmat1, M.R. Baghaeipour1, N.B. Mirbehbahani6, R. Fayazfar7, M. Ahmadinejad1, R. Eshraghi8, M. Naderi4 (1Tehran, IR; 2Shiraz, IR; 3Isfahan, IR; 4Ahwaz, IR; 5Karaj, IR; 6Gorgan, IR; 7 8

Friday, February 14, 2014 Friday, Kerman, IR; Maywood, US) 80 Poster Sessions – Friday, February 14, 2014

P26-10 A Non-invasive Approach for Monitoring Patients Undergoing Anticoagulant Therapy T. Lomonaco, S. Ghimenti, I. Piga, M. Onor, R. Fuoco, A. Paolicchi, G. Pellegrini, L. Ruocco, M.G. Trivella, F. Di Francesco (Pisa, IT)

P27 Omics and Microparticles

Chair: I. Seljeflot (Oslo, NO)

P27-1 Hemostasis Poly Vinyl Alcohol Gauze Coated With Chitosan Encapsulated With Polymer and Drug A. Ramasamy (Madurai, IN)

P27-2 Characterization of Platelets with High and Low Mean Platelet Volume Using 2D-DIGE and Atomic Force Microscopy T. Thiele, S. Wiersbitzky, T.H. Nguyen, M. Delcea, M. Gesell Salazar, U. Völker, A. Greinacher, L. Steil (Greifswald, DE)

P27-3 The Influence of Endothelial Cell-derived Microparticles on Clotting Time in Thromboelastometry C. Bonstingl, S. Riedl, P. Hofbauer, S. Weilner, J. Zipperle, J. Grillari, H. Redl, H. Schöchl, C. Schlimp, W. Holnthoner (Vienna, AT)

P27-4 Application of the Next- generation Sequencing Technique to Diagnostic Sequence Analysis of the VWF Gene. Evaluation and Development of Protocols S. Sollfrank, H. Schinzel, I. Scharrer, K.J. Lackner, H. Rossmann (Mainz, DE)

P27-5 Genetic Background of Plasminogen Deficiency in Four Individuals S. Körber1, C. Heller1, C. Wermes2, M. Krause3, B. Luxembourg1, D. Topolar1, E. Seifried1, C. Geisen1 (1Frankfurt, DE; 2Hannover, DE; 3Wiesbaden, DE)

P27-6 Smoking Alters Circulating Plasma Microvesicle Composition and Microrna Profile S. Badrnya, R. Baumgartner, A. Assinger (Vienna, AT)

P27-7 The A+-helix of PCI, Which is Removed by Testisin Cleavage, is a Cell Penetrating Peptide and Responsible for Internalization of PCI by Jurkat H. Yang, M. Geiger (Vienna, AT) Friday, February 14, 2014 Friday, 81 Poster Sessions – Friday, February 14, 2014

P28 Platelet Aspects IV

Chair: U. Walter (Mainz, DE)

P28-1 Lack of Peripheral Serotonin Limits Platelet-neutrophil Complex Formation and Reperfusion Injury During Myocardial Infarction in Mice M. Mauler, A. Maier, A. Ortiz-Rodriguez, C. Bode, A. Zirlik, D. Duerschmied (Freiburg, DE)

P28-2 Clot Retraction is Mediated by Factor XIII-dependent Fibrin-alphaIIbbeta3- myosin Axis in Platelet Sphingomyelin-rich Membrane Rafts K. Kasahara (Tokyo, JP)

P28-3 Hydrophobic Regions on Protein Surfaces Induce Platelet Activation by vWf, HOCl Modified Albumin and Alzheimer’s Amyloid Beta Peptide. M. Brodde1, A. Bertling1, K. Jurk1, C. Heilmann1, J. Lahav2, J. Nofer1, B. Kehrel1 (1Münster, DE; 2Petah Tikva, IL)

P28-4 Modulation of Platelet Activation and Thrombin Generation by a Phosphatase Inhibitor R. Hudák, I. Debreceni, F. Erd di, J. Kappelmayer (Debrecen, HU)

P28-5 The Role of Kindlin-3, as a Regulator of Integrin Activation M. Eberhard, M. Gyenes, J. Neuhann, R. Scharf (Düsseldorf, DE)

P28-6 First Characterization of Platelets from Patients with Familial Hemophagocytic Lymphohistiocytosis Type 3 (Fhl-3) L. Nakamura1, A. Bertling2, M. Brodde2, U. Zur Stadt3, K. Beutel1, B. Zieger1, B. Kehrel2 (1Freiburg, DE; 2Münster, DE; 3Hamburg, DE)

P28-7 Phospholipase-mediated Crosstalk Between Orai1 and TRPC6 in Murine Platelets W. Chen1, I. Thielmann1, S. Gotru1, S. Gupta1, H. Subramanian1, D. Stegner1, R. Kruchten2, A. Dietrich3, S. Gambaryan1, J. Heemskerk2, H. Hermanns1, B. Nieswandt1, A. Braun1 (1Würzburg, DE; 2Maastricht, NL; 3Munich, DE)

P28-8 The Role of Magnesium Transporter MagT1 in Murine Platelets S. Gotru, P. Kraft, S. Stritt, M. Morowski, G. Stoll, W. Chen, B. Nieswandt, A. Braun (Würzburg, DE) Friday, February 14, 2014 Friday, 82 Exhibition

The organizers wish to express their gratitude to the exhibitors for participating in the 58th Annual Meeting of the GTH. Participants are invited to visit the commercial exhibition throughout the congress center.

Opening Hours Exhibition Wednesday, February 12, 2014 12:00 – 21:00 Thursday, February 13, 2014 08:30 – 18:30 Friday, February 14, 2014 08:30 – 19:00

The exhibition service desk is located on the ground level at the entrance of the congress center.

List of Exhibitors The following companies will be exhibiting at the GTH 2014 (alphabetical order):

Alere GmbH INTERSERO GmbH ALEXION Pharma Germany GmbH IUL-Instruments GmbH American Diagnostica GmbH Keller Medical GmbH Axon Lab AG LEO Pharma GmbH Baxter Deutschland GmbH LFB Biomedicaments BAYER Healthcare Mitsubishi Pharma Deutschland GmbH BFSH e.V. möLab GmbH Biotest AG Nordic Pharma GmbH BitMedical GmbH Novo Nordisk Pharma GmbH Boehringer Ingelheim RCV GmbH & CoKG Octapharma GmbH Bristol-Myers Squibb GmbH Pfizer Corp. Austria GmbH / Pfizer Pharma GmbH CELLSYSTEMS Biotechnologie Vertrieb GmbH Probe & go Labordiagnostica GmbH CoaChrom Diagnostica GmbH Referenzinstitut für Bioanalytik (RfB) CSL Behring GmbH Roche Diagnostics Deutschland GmbH Daiichi Sankyo Deutschland GmbH SANOFI DSM Nutritional Products Ltd / Pentapharm Schattauer GmbH Ferring Arzneimittel GmbH Sekisui Virotech GmbH Grifols Deutschland GmbH Siemens Healthcare Diagnostics GmbH Haemochrom Diagnostica GmbH Sobi Haemonetics GmbH Stago Deutschland GmbH ICI Immunochemical intelligence GmbH Technoclone GmbH Instrumentation Laboratorys GmbH International Self-Monitoring Association of oral Anticoagulated Patients (ISMAAP) (as per December 2013)

83 General Information Vienna

About Vienna Whether this is your first visit to Vienna or you have been here before – this city always finds ways to surprise and delight you. Just take in its atmosphere, which is rich in history and tradition, yet also fresh and upbeat. The city centre is a small universe in itself: discover historical palaces face to face with modern facades, ele- gant boutiques next to popular fashion stores, and antique shops lining up across from stylish designer hotspots. Art permeates Vienna’s very essence – get a feel of it during a city walking tour, or while visiting one of Vienna’s many museums. Must-sees include the Kunsthistorisches Museum, Albertina and the museums located in the trendy Museumsquartier (MQ). Sights not to be missed are St. Stephen’s Cathedral right in the heart of the city, Schönbrunn palace, and the Giant Ferris Wheel at the „Prater” fairground. Fans of classical music and opera lovers may jump at a chance to spend an evening at the Staatsoper or the Musikverein. More modern fare can be found at Vienna’s jazz bars, world music pubs and dance clubs. When it comes to food, you should definitely try famous Austrian dishes such as „Wiener Schnitzel” (breaded escalope of veal) or „Tafelspitz” (prime boiled beef). Your stay isn’t complete without treating yourself to coffee and a slice of cake at one of Vienna’s coffeehouses, or trying some organic ice cream.

If you are interested in sightseeing tours or more touristic information about Vienna, please visit the Tour & Concert Counter in the registration area. Useful information on Vienna as well as an event calendar to be found online at www.wien.info

Weather Conditions in Vienna Vienna, the largest city of Austria, lies between a transition of humid continental and oceanic climate. Weather is cold in winter, the average maximum temperature is 4 degrees Celsius, the minimum averages at minus 1. Snow can be expected every now and then.

Electricity & Time The main voltage in Austria is 220V. Vienna is in the Central European Time Zone, Greenwich Mean Time (GMT) +1hour.

Shopping Shops are usually open from 10:00-19:00 from Monday to Friday and from 10:00-17:00 on Saturday. On Sunday shops are usually closed except in the old town. Grocery stores already open around 8:00 during weekdays.

Tipping Service is usually included in the prices in bars and restaurants. Tips are always welcome and usually 10%.

Banks & Local Currency Banking hours in general are Monday, Tuesday, Wednesday, Friday 08:00 – 12:30 and 13:30 – 15:00, Thursday 08:00 – 12:30 and 13:30 – 17:30. ATMs are located outside most banks, cash can be withdrawn there 24/7. National and foreign Maestro cards (cash cards) as well as Mastercard, AMEX, Visa and Diners are accepted. A Cash machine can be found at the nearby Raiffeisenbank (Loos-Haus on Michaelerplatz). 84 General Information Vienna

Useful Telephone Numbers Ambulance: 144 Taxi: +43 1 31 300 Police: 133 +43 1 40 100 Fire Brigade: 122 +43 1 60 160

Travel to Vienna

Access by Plane 73 international airlines offer scheduled services to Vienna. There are several daily flights between Vienna and the main European capitals and business centres. Austrian Airlines, the country’s flag carrier, connects 116 cities worldwide with Vienna and offers modern aircrafts and excellent service. Vienna International Airport at Schwechat, 19 km (12 miles) from the city centre, is state-of-the-art in every respect.

Access by Car/Coach Austria’s expressway network reaches right into Vienna, allowing a comfortable and convenient trip to Vienna by car or coach from any point on the European continent.

Access by Train Vienna occupies a hub position in Europe’s international railway network. Intercity and international express trains are connecting cities of all parts of Austria and all major European destinations with Vienna.

From the Airport to the City Centre and Vice Versa Bus: At 20-minute intervals, the Vienna Airport Lines depart between 05:30 and 24:00 daily. Cost: approx. € 8,–. Duration: approx. 20–30 min. Train: The urban railway leaves at 10-30 min. intervals between 05:00 and 22:00 daily. Cost: approx. € 4,–. Duration: approx. 30–40 min. CAT: The City Airport Train runs at 30-minute intervals from 06:05 to 23:00 daily from the airport to train station „Landstrasse/Wien Mitte“. Cost: approx. € 10,–. Duration: approx. 16min. Car: Take Autobahn A4 from the Airport to Vienna. The city centre is signposted.

Public Transportation in Vienna Hofburg Vienna (U2, U3 Volkstheater) as well as all hotels can easily be reached using Vienna’s efficient and modern public transport network of underground lines, trams and busses. Depending on the line in question, hours of operation are between 5:00 and 00:30 daily. Prices Single Trip Ticket € 2.20,– 24 Hours € 7.10,– 48 Hours € 12.40,– 72 Hours € 15.40,– 72 Hour Tickets can be purchased at the Tour & Concert Counter in the registration area on the ground level of the congress center. Further public transportation tickets are available at Vienna Transport Authority´s ticket offices, as well as at the ticket machines in all underground stations. 85 City Map Vienna

86 Underground Map Vienna

87

Printed in Austria by: ROBIDRUCK, A-1200 Vienna – www.robidruck.co.at